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ABSTRACT 
 
Characterization of the Meq Oncoproteins of  
Marek’s Disease Virus Vaccine Strain CVI988/Rispens. (May 2009) 
Dharani Kumar Ajithdoss, B.V.Sc., Tamil Nadu Veterinary and Animal Sciences 
University; M.V.Sc., A.N.G.Ranga Agricultural University  
Chair of Advisory Committee: Dr. Blanca Lupiani 
 
 Marek’s disease virus serotype-1 (MDV-1) causes T cell lymphomas in chickens. 
Vaccines prepared from attenuated CVI988/Rispens MDV-1 strain currently offer the 
best protection. Although attenuated CVI988 is non-oncogenic, it codes for two forms of 
the MDV-1 oncoprotein Meq (CVI-Meq and CVI-L Meq). In this study, both CVI-Meq 
proteins, like the Meq protein of Md5 (a very virulent oncogenic strain), transformed 
Rat-2 and NIH3T3 cells. Both CVI-Meq and CVI-L Meq proteins activated the meq 
promoter only in the presence of chicken c-Jun (CK-Jun) whereas Md5-Meq activated 
the same promoter irrespective of CK-Jun co-expression. However, all three Meq 
proteins bound the meq promoter regardless of whether CK-Jun was co-expressed. We 
constructed three chimeric Meq proteins, namely, Md5-CVI-Meq, CVI-Md5-Meq, and 
Md5-CVI-L by exchanging domains between Md5 meq and CVI meq genes. Although 
these chimeric Meq proteins transactivated the meq promoter, the activation was 
significantly less than Md5-Meq. The current study indicated amino acid residues at 
positions 71 and 320 were important for Md5-Meq increase transcription of its own 
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promoter. All three Meq proteins activated the MDV gB, MMP-3 and Bcl-2 promoters 
and suppressed transcription from the MDV pp38/pp14 bidirectional promoter.  
CVI-Meq protein in the context of other Md5 genes caused tumors only in 6% of 
chickens when compared to parental rMd5 (a very virulent strain), which induced 
lymphomas in 100% of chickens, (Reddy and Lupiani, unpublished data). Taking 
advantage of these two different phenotypes, we constructed two chimeric Meq proteins, 
Md5/CVI-Meq and CVI/Md5-Meq, by exchanging DNA binding and transactivation 
domains between Md5-Meq and CVI-Meq to understand the role of the DNA binding 
and the transactivation domains of Meq in transformation. rMd5-Md5/CVI-Meq virus 
caused 100% mortality in chickens and T lymphomas were found at high frequency in 
the peripheral nerves and various organs such as the heart, spleen, kidney, and gonads. 
On the other hand, rMd5-CVI/Md5-Meq induced disease in 36% of chickens on average 
and lesions were primarily in the nerves. Very rarely, lesions were present in the spleen 
and heart and no tumors were present in the kidney or gonads. Our results suggest that 
both the DNA binding domain and transactivation domain of Meq could cooperatively 
determine the nature of lymphomas in chickens. 
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NOMENCLATURE 
 
bZIP Basic leucine zipper 
CEF Chicken embryo fibroblast 
CHIP Chromatin immunoprecipitation assay 
CK-Jun Chicken c-Jun 
CtBP C-terminal-binding protein 
DBD DNA binding domain 
DEF Duck embryo fibroblast 
EARC Ellipsoid-associated reticular cells 
ECM Extracellular matrix 
FFE Feather follicular epithelium 
GaHV Gallid herpesvirus 
gB Glycoprotein B 
HSV-1 Herpes simplex virus type 1 
IRL Internal repeat long 
IRS Internal repeat short 
LAT Latency associate transcript 
MDV Marek’s disease virus 
Meq Marek’s EcoQ fragment 
MERE Meq response element 
MMP-3 Matrix metallo-proteinase-3 
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NLS  Nuclear localization signal 
NoLS Nucleolar localization signal 
Ori Origin of replication 
PCR Polymerase chain reaction 
REV Reticuloendothelial virus 
SEM Standard error of mean 
SPF Specific pathogen free 
TAD Transactivation domain 
TRL Terminal repeat long 
TRS Terminal repeat short 
UL Unique long 
US Unique short 
vLIP Viral lipase 
vTR Viral telomerase RNA gene 
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1. INTRODUCTION 
1.1. History of Marek’s disease 
Marek’s disease (MD) is a common, highly contagious, malignant lymphoma of 
chickens characterized by lymphoid infiltrations in peripheral nerves, visceral organs, 
eye, muscle, and skin, contributing to significant economic losses to the world chicken 
industry. MD was named in honor of the Hungarian veterinarian, Joseph Marek, who 
first described the condition in four adult male chickens in 1907 (Biggs, 1961; Marek, 
1907).  He described the disease as a "polyneuritis" or a “neuritis interstitialis”, 
characterized by paralysis of the legs and wings. Grossly, the sacral plexuses and spinal 
cords were thickened, and microscopically, many of these nerves had mononuclear 
infiltration. In America, the disease was first reported as “ paralysis of the domestic 
fowl” (Kaup, 1921). Soon after, a similar condition, named as “ neuromyelitis 
gallinarium” was reported in The Netherlands (Van der Walle and Winkler-Junius, 
1924). At that time, the disease was commonly known as “fowl paralysis”, “range 
paralysis” or “ Marek’s paralysis”. In addition to the peripheral nerves, mononuclear 
infiltration was also found in visceral organs in 10% of chickens that showed paralysis 
(Pappenheimer et al., 1929). Although most common in the ovary, tumors were also 
found in the liver, kidneys, lungs, adrenals, and muscle. The authors named this 
condition as “ neurolymphomatosis gallinarium”. Because of lymphoid tumors and 
difficulty in differential diagnosis, the disease was often confused with lymphoid  
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leukosis, also a neoplastic disease caused by avian leukosis virus (Biggs, 1961; 
Campbell, 1961; Ellermann, 1922). Based on susceptibility, organs affected, and 
histopathogenesis, the disease can be distinguished from lymphoid leucosis and a new 
name, Marek’s disease, was proposed (Biggs, 1961). Later, it was clearly established 
that these two diseases are separate and caused by two different agents (Biggs and 
Payne, 1964).  
1.2. Etiology of Marek’s disease 
When chickens were inoculated with blood and tumor cell suspensions obtained 
from diseased birds, both inoculated and uninoculated contact chickens developed MD, 
indicating that the disease is readily transmissible (Biggs and Payne, 1963; Sevoian et 
al., 1962). These, and other studies have revealed that MD causative agent is highly cell-
associated as cell free suspension failed to cause cytopathic effect in cell culture as well 
as disease in chickens (Churchill, 1968; Solomon et al., 1968). By identifying 
transformed cells were of host origin through the use of sex chromosomes markers, the 
possibility of cell transplantation causing the disease was ruled out (Owen et al., 1966). 
Electron microscopic examination of chicken kidney cells infected with blood and tumor 
cells revealed virus particles, whose morphology resembled those of herpesviruses 
(Churchill and Biggs, 1967). Subsequently, presence of herpesvirus like particles in 
infected duck embryo fibroblasts was also reported (Nazerian and Burmester, 1968). 
These studies have established that a herpesvirus, called as Marek’s disease virus 
(MDV), is the etiology of the disease. Vaccines prepared by virus attenuation in cell 
culture (Biggs et al., 1970; Churchill et al., 1969a; Churchill et al., 1969b) and from 
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MDV related virus from a turkey, herpesvirus of turkeys (HVT) (Okazaki et al., 1970) 
protected chickens against MD; these studies provided conclusive evidence that MDV is 
the etiological agent of MD. 
1.3. Classification 
 Presently, MDV serotype 1, officially known as Gallid herpesvirus 2 (GaHV-2), 
is classified as a member of the order Herpesvirales, family Herpesviridae, subfamily 
Alphaherpesvirinae and genus Mardivirus (Davison et al., 2008). Two other members in 
the genus Mardivirus are Gallid herpesvirus 3 (previously MDV-2), and Meleagrid 
herpesvirus 1 (previously MDV-3 or HVT) (Davison et al., 2008). 
Three methods are widely used to classify MDV isolates (Fig. 1). In the 
beginning, MDV isolates, which caused lesions only in nerves and lesions in both nerves 
and visceral organs were classified as classical and acute, respectively (Biggs et al., 
1965). Based on the antigenic differences, MDV was later classified into three serotypes: 
MDV serotype 1 (MDV-1), MDV serotype 2 (MDV-2), and MDV serotype 3 (MDV-3 
or Herpesvirus of Turkeys, HVT) (Bulow and Biggs, 1975a; Bulow and Biggs, 1975b). 
Among these three serotypes, only MDV-1 causes disease in chickens. The virulence of 
MDV seems to increase over a period of time with the introduction of new vaccines; it is 
speculated that intense vaccination is one of the reasons for continuous virus evolution. 
Based on the lesions such as increased cytolytic infection, uncommon cell tropism, 
severe lymphoid organ atrophy, early mortality, severe suppression of immune system, 
and aggressive tumors in chickens that are vaccinated with turkey herpesvirus (HVT)  
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Fig. 1. Classification of MDV isolates.  
 
and bivalent (HVT + SB-1), MDV isolates are classified into mild (m), virulent (v), very 
virulent (vv), and very virulent plus (vv+) pathotypes (Witter, 1997). Though 15 X 7 
chickens available in Avian Disease and Oncology Laboratory, USA were initially used, 
this classification can also be done by using specific pathogen free (SPF) chickens 
(Dudnikova et al., 2007). 
1.4. Genome and its organization 
The genome of MDV is large, linear, double-stranded DNA with a buoyant 
density of 1.715 gm/cm2 (Lee et al., 1971) and represents class E, identical to herpes 
simplex virus type 1 (HSV-1), in genome organization. It comprises of two unique DNA 
segments called a unique long (UL) and a unique short (US), which are flanked by large 
inverted repeated sequences (Fig. 2). The flanking DNA sequences of UL are called as 
terminal repeat long (TRL) and internal repeat long (IRL) and that of US are known as 
terminal repeat short (TRS) and internal repeat short (IRS).  
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Fig. 2. MDV genome. It is composed of unique long (UL) and unique short (US) 
segments, flanked by inverted repeats. The inverted repeats are: TRL: terminal repeat of 
the long segment; IRL: internal repeat of the long segment; IRS: internal repeat of the 
short segment; and TRS: terminal repeat of the short segment. Most of unique genes are 
located in the repeat long regions. The direction of transcription and relative positions of 
genes transcribed in this repeat are noted. Among these, Meq is of particular importance 
due to its requirement for transformation. 
 
 
These flanking sequences can invert their orientation relative to unique segment, 
thus producing four isomeric forms during virus replication. The complete nucleotide 
sequences for many MDV strains are currently available. The genome of a very virulent 
strain of MDV-1, Md5, contains 177, 874 bp, which is predicted to code for at least 103 
proteins (Tulman et al., 2000). The 64 genes located in UL region are important for virus 
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replication and virus assembly. Most of these genes are highly homologous and 
corresponds to those present in UL region of human alphaherpesvirus, herpes simplex 
virus type 1 (HSV-1). Among six genes that are unique to MDV, viral lipase (vLIP) has 
been identified as one of the virulent factors of MDV (Kamil et al., 2005). Out of nine 
genes in the US region, seven are found in HSV-1 US DNA segment. Two genes that are 
unique to MDV are MDV090 and MDV093 with presently unknown functions. The 
short repeat regions (TRS, and IRS) contain 12 genes; many of them including immediate 
early proteins, ICP4, ICP22, and ICP27 are found in HSV-1. Unlike unique regions and 
the short repeat regions, 16 genes located in the long repeat regions (TRL, and IRL) are 
exclusively present in MDV-1 genomes and are not found in other MDV serotypes or 
non-avian herpesviruses. Many of these genes (meq, pp38, pp24, vTR, and vIL-8) are 
associated with MDV pathogenesis (Brown et al., 2006; Cui et al., 2004; Lupiani et al., 
2004; Parcells et al., 2001; Reddy et al., 2002).  
The GA (a virulent MDV strain) genome is 174, 078 bp long, which unlike Md5 
strain, contains U3 sequences from reticuloendothelial virus (REV) near the UL/ IRL 
junction (Lee et al., 2000a). The significance of this retrovirus insertion remains to be 
studied.  
The genome size of another MDV virulent strain, Md11, is 170,950 bp (Niikura 
et al., 2006). Interestingly, the terminal short region in this genome is completely 
replaced with a portion of duck chromosome 19. The complete DNA sequence vaccine 
of strain CVI988, a non-oncogenic MDV strain, consists of 178,311 bp (Spatz et al., 
2007a). When compared with genomes of MDV oncogenic strains, there are several 
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differences present in the CVI988 genome. These include a 177 bp insertion in the meq 
region, deletions in ORFs 49.1, 5.5, and 3.0 (vIL-8), nucleotide changes in UL36 and 
UL49 (tegument genes), and absence of ORF6.2.  
In addition to MDV-1, the complete genome sequences of MDV-2 and HVT are 
also available. Its organization, similar to MDV-1, is collinear with and closely related to 
HSV-1 genome. The genome of HPRS16, MDV-2 strain, is 164,270 bp in length and 
contains 91 ORFs. HVT strain FC-126 genome size is 159,160 bp or 160, 673, which is 
estimated to code for 99 proteins (Afonso et al., 2001; Kingham et al., 2001). Sixteen 
genes that are present in MDV-1 strains are absent in HVT genome including meq 
(MDV oncogene), pp24 and pp38 (MDV early replication proteins), and vIL-8 (MDV 
chemokine), which are important for MDV pathogenesis. Conversely, 13 genes of HVT 
are absent in MDV-1 genomes. Notably, HVT contains NR-13 gene, a Bcl-2 homologue 
of quail and has been shown to inhibit apoptosis in the DT40 (a B cell line) (Ewert and 
Duhadaway, 1999). 
1.5. Stages of MDV infection 
 Infectious virus is shed along with the debris of dead stratified feather follicular 
epithelial cells, which serve as a source of infection for chickens. The infection is 
usually acquired through inhalation of infected poultry house dust and chicken dander 
(Beasley et al., 1970). The virus soon reaches the lung through unknown mechanisms. 
According to ‘Cornell Model’, MDV pathogenesis in chickens is divided into four 
phases: an early cytolytic phase, a latent phase, a late cytolytic and immunosuppressive 
phase, and a transformation phase (Calnek, 1986) (Fig. 3). 
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Fig. 3. Biology of MDV. Following inhalation, the virus reaches the lung. Macrophages 
are believed to carry the virus to lymphoid organs (spleen, thymus and bursa), where it 
undergoes cytolytic infection mostly in B cells and in few T cells. Thereafter, the virus 
establishes latency only in T cell at 7 dpi. After a week, second cytolytic infection is 
seen in lymphoid organs as well as in epithelial tissues such as feather follicular 
epithelial cells (FFE). Cell-free virus is released only from FFE in chickens, which is the 
source of infection for susceptible chickens. The hallmark of MDV infection is the 
transformation of latently infected T cells, occurs as early as three weeks. 
 
 
1.5.1. Early cytolytic phase 
It is commonly believed that MDV is transported from the lung to the spleen and 
caecal tonsil by macrophages. Expression of MDV antigens such as pp38 (an immediate 
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early protein) can be demonstrated in the spleen 4-6 days post-infection (Baigent et al., 
1998) and not at or after 8 dpi, coinciding with the onset of virus latency (Baigent and 
Davison, 1999). This productive-restrictive phase is characterized by genome expression 
and production of intracellular virions; but cell-free infectious virus particles are not 
produced. There is evidence that the virus interacts with antigen presenting cells such as 
ellipsoid-associated reticular cells (EARCs) after entering into the spleen (Jeurissen et 
al., 1989). In the spleen, 95% of MDV infected lymphocytes are B cells, which are in 
close contact with EARCs, while 4% are double positive CD4+ CD8+ T cells (Baigent et 
al., 1996). As the name indicates, the outcome of this infection is destruction of cells. 
Additionally, splenomegaly due to reticular hyperplasia commonly occurs. It is 
noteworthy that resting T lymphocytes are resistant to cytolytic infection. However, 
activation of these resting cells occurs at the end of this phase, more likely, due to 
relocalization of T cells into the proximity of infected B cells leading to infection 
(Baigent and Davison, 1999). Interestingly, the spleen is not essential for MDV 
pathogenesis since neonatal splenectomy did not affect the viremia in chickens (Schat et 
al., 1980). Besides the spleen and caecal tonsil, virus replication at lower level can also 
occur in the thymus and bursa. It is speculated that the source of infection for these 
organs is the infected B-lymphocytes from the spleen and caecal tonsil. Marked 
reduction in the size of the bursa was noted in chickens infected MD agents, JM and 
Conn-A (Jakowski et al., 1969) . Further, necrosis of follicles and loss of follicles in 
many bursas were observed microscopically. Similar lesions were also reported in the 
thymus (Purchase and Biggs, 1967) .  
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1.5.2. Latent phase 
 MDV enters into latency 7 dpi.  Like in other herpesviruses, there is no 
expression of viral protein or infectious virus production during MDV latency. However, 
viral genomes and few latency-associated transcripts (LATs) including two MDV small 
RNAs (0.9 and 0.75 kb) and a 10-kb RNA can be found in latently infected cells 
(Cantello et al., 1994). In stark contrast to the early cytolytic infection, the majority of 
latently infected cells are T lymphocytes, with few B cells (Calnek et al., 1984; Shek et 
al., 1983). These latently infected T lymphocytes retain the virus life long, serving as a 
virus reservoir. Because of lack of suitable experimental systems that differentiate 
latently infected cells from transformed cells, mechanisms of latency are yet to be 
understood. In this regard, it is of interest to note that cell-mediate immune response, not 
humoral response, can influence the development and maintenance of latency (Buscaglia 
et al., 1988; Schat et al., 1980).  
1.5.3. Late cytolytic phase and immunosuppression 
  At 14-21 dpi, virus replication resumes in the thymus and bursa (Calnek, 1986). 
At the same time, virus replication also occurs in the kidney, esophagus, feather 
follicular epithelium (FFE), adrenal gland and proventriculus. At present, knowledge 
regarding the source of infection for these epithelial tissues is lacking. Replication in 
FFE is of particular importance since it is the only site, where productive infection 
occurs resulting in the release of cell-free virus along with dead epithelial cells into the 
environment (Calnek et al., 1970). Immunosuppression involving both humoral and CMI 
response is associated with this phase as demonstrated in several studies (Calnek et al., 
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1979; Friedman et al., 1992; Lee et al., 1978; Rivas and Fabricant, 1988), and is 
apparently due to the cytolytic infection in the thymus and bursa. 
1.5.4. Transformation 
 Transformation of latently infected T lymphocytes occurs at 21-28 dpi and is the 
hallmark of MDV infection. The phenotype of these neoplastic cells, which resembles 
that of activated T helper-2 cells, is CD4+, TCR αβ+, CD30hi, CD28lo/-, MHC class Ihi, 
MHC class IIhi, IL-2α+, MDV pp38-, and MDV gB- (Burgess and Davison, 2002). 
Besides transformed T lymphocytes, other cells such as B lymphocytes, macrophages, 
and reticular cells are also present in the lymphomas albeit at very low percentage. As 
early as 3 weeks, neoplastic cells can be found in peripheral nerves, muscles, skin, and 
visceral organs such as the adrenal gland, heart, intestine, kidney, liver, lung, ovary, 
proventriculus, spleen, eye, and thymus. Factors such as virus serotype and pathotype 
(Witter, 1997), chicken genotype (Baigent and Davison, 1999), age at infection (Calnek, 
1973), maternal antibodies (Calnek, 1972), and vaccination (Witter, 1997) greatly 
influence the tumor incidence. It is still unclear whether latently infected cells become 
transformed following infiltration or alternatively, cells that are transformed elsewhere 
infiltrate these sites.  
 It was first proposed that MD tumors were monoclonal in nature because latently 
infected lymphocytes collected from multiple organs of the same chicken had identical 
pattern of integration (Delecluse et al., 1993). Recent study, in contrast, suggests that 
they are polyclonal as the population contain both TCR2+ and TCR3+ cells, products of 
two different chicken TCR variable beta chain genes (Burgess and Davison, 2002). Cell 
 12 
lines have been established from MD lymphomas (Akiyama et al., 1973; Powell et al., 
1974). Depending upon the cell lines, MDV genome can be found as episomal (Tanaka 
et al., 1978) or integrated (Kaschka-Dierich et al., 1979) or both (Kaschka-Dierich et al., 
1979). 
1.6. Symptoms in chickens 
 Clinical signs in chickens vary according to the susceptibility, virus strain, age at 
infection, maternal antibodies, and vaccination status. Affected chickens exhibit 
neurological signs such as paresis or paralysis of the legs and wings, which may be 
either spastic or flaccid, dyspnea, torticollis, and paralysis of the tail and eyelids. 
Transient paralysis is often seen in young chickens due to temporary vasogenic edema in 
the CNS (Swayne et al., 1989). Some birds develop blindness because of neoplastic and 
inflammatory lesions in the eye, commonly referred as “pearly eye” or “gray eye” or “ 
ocular lymphamatous” (Ficken et al., 1991; Smith et al., 1974). In the early-mortality 
syndrome, chickens infected with highly pathogenic strains suddenly die with wasting at 
12-13 dpi and show no neurological signs (Witter et al., 1980). 
1.7. Pathology of MD 
 Macroscopically, enlargement of the peripheral nerves such as the brachial 
plexus and sciatic plexuses, and vagus is commonly found. This may be unilateral or 
bilateral. Further, depending upon the virulence of strains, gross tumors are present in 
various organs including the ovary, testicles, liver, spleen, kidney, intestines, heart, 
proventriculus, and eye. 
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Microscopic nerve lesions in advanced MD cases are classified into three types: 
1. Type I: infiltration of small lymphocytes and plasma cells with little edema; 2. Type 
II: infiltration of few lymphocytes with marked edema and fibrosis; 3. Type III: 
infiltration of neoplastic lymphoid cells (Wight, 1962). It was noted that neoplastic 
infiltration was secondary to the inflammation. However, a subsequent study, focused on 
chronology of disease development in chickens infected experimentally showed that the 
lesions were due to primary neoplastic process (Payne and Biggs, 1967). The nerve 
lesions were classified into 3 types: (a) Type A: increased proliferation of lymphoid cells 
and Schwann cells, and demyelinization seen in 14 to 21 dpi; (b) Type B: a diffuse 
infiltration of lymphoid cells and some edema see in later stage of disease; (c) Type C: a 
little infiltration of lymphoid cells seen in clinically normal, mature chickens. 
Furthermore, the nerve lesions based on electron microscopic observations were 
classified into 3 types: (1) Type 1: infiltration of small lymphocytes; (2) Type 2: 
infiltration of small, medium, and large lymphocytes; (3) Type 3: infiltration of small 
lymphocytes, plasma cells and reticular cells (Okada and Fujimoto, 1971). Lesions in 
visceral tumors were similar to those in peripheral nerves  (Nazerian, 1973) . 
1.8. MDV vaccines 
MD is the first neoplastic disease in the history against which successful vaccines 
were developed. Vaccines prepared from all three serotypes are being used either alone 
or in combination for the control of MD around the world. 
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1.8.1. Serotype 1 vaccines 
The oncogenicity of MDV-1 strain HPRS-16 has been reported to be lost in 
chickens following a serial passage for 33 times in the chicken kidney cells, which 
suggested for the first time that MDV could be attenuated by repeated passage in cell 
culture (Churchill et al., 1969a). Notably, chickens vaccinated with thirty-first passage of 
HPRS-16 virus were protected against the challenge by direct inoculation or by contact 
exposure of fourteenth passage virulent virus (Churchill et al., 1969b). This was the first 
protection study that demonstrated the feasibility of using attenuated MDV as a vaccine. 
This type of attenuation is not strain specific as JM strain that was passaged in DEF or 
CEF for 100 times also failed to cause MD in susceptible chickens (Nazerian, 1970). 
Interestingly, progeny from a parental stock vaccinated with a cell culture attenuated GA 
strain were protected against the challenge with the virulent GA strain, indicating the 
role of maternal antibodies in vaccine-mediated protection (Eidson et al., 1971). The 
protective efficiency of an attenuated MDV strain in a major field trial that used more 
than 32,000 commercial birds was reported to be 80 % (Meulemans et al., 1971). 
Currently, vaccines prepared from CVI988 strain offer the best protection and are widely 
used in the USA and Europe and the characteristics of this strain will be discussed in 
detail here. CVI988, a MDV avirulent strain, was originally isolated from MDV positive 
but MD and ALV disease free eleven-months-old laboratory flock, maintained in semi-
isolation at the Central Veterinary Institute, The Netherlands (Rispens et al., 1972). This 
strain caused neither disease nor death in experimentally inoculated chickens. 
Importantly, the virus (CVI988-4) that was passaged four times in DEF protected 
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chickens against a challenge with the strain K, a virulent MDV.  In the absence of 
vaccination, the strain K caused 43% mortality, which was reduced to 1% following 
CVI988-4 vaccination. In this experiment, CVI988-4 caused C-type microscopic lesions 
in the nerves in few chickens. To avoid this, CVI988-4 was further passaged in DEF. 
CVI988 -26 virus at the level of 26th passage did not induce microscopic lesions in the 
nerves and was completely attenuated. Further, this virus provided 97-100% protection 
in various genetic chicken lines against the strain K challenge. In DEF, the CVI988-26 
formed a syncytial type of microplaque, characterized by rounding and darkening of 
cells with more than 100 nuclei.  Comparable plaques were also observed in CVI 988-26 
infected CEF. This strain was safe to use as vaccine for chickens even at the dose of 
300,00 PFU. Isolation of CVI988-26 from vaccinated chickens was variable (30-75%). 
Though the virus spreads to contact birds, the isolation was even lower (5-30%) from 
them. Vaccinated birds excreted virus by 3rd week. Contact birds were viremic for 
CVI988-26 by 4th week and virus demonstration in feather follicle was possible by 5th 
week. Notably, it provided excellent protection (98-100%) against the strain K 
challenge, irrespective of whether the challenge was done at day-old or 4 weeks post 
vaccination. This level of protection was effective for 2 years. The virus maintained its 
avirulence and did not revert back to induce any microscopic lesions. It was apathogenic 
for Rhesus monkeys and humans handling chickens and vaccines did not show any 
MDV antibodies. Intramuscular route of vaccination was preferred over intraperitoneal 
because non-specific mortality was found to be fewer with the former than the later. 
Minimum dose required for vaccination was determined to be 3,000 PFU. Partial 
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vaccination at the level of 10 % did not offer good protection. The level of protection 
offered by CVI988-26 was superior to that of HVT. MD mortality following vaccination 
with CVI 988-26 and HVT were 1.25% and 5-8.75 %, respectively.  
Although several virulent MDV-1 strains have been attenuated over many 
decades in order to develop them as potent vaccines, the protective efficiency of all of 
them is inferior when compared to that of CVI988. That being said, rMd5ΔMeq virus 
has been recently reported to provide better protection than CVI988 in the laboratory 
chickens (Lee et al., 2008). It is important, however, to evaluate the efficacy of this 
vaccine in commercial chickens. 
1.8.2. Serotype 2 vaccines 
  The SB-1 strain, originally isolated from 28-week-old unvaccinated, MD free S-
strain chickens, was nononcogenic even in immunosuppressed chickens and offered 
protection against virulent virus (Schat and Calnek, 1978). The strain 301B/1, isolated 
from MD disease free chickens, provided a protection comparable to that of SB-1 strain 
(Witter, 1987). These two strains have been approved to use in the USA and are 
commonly used as a bivalent vaccine in combination with HVT. 
1.8.3. Serotype 3 vaccines 
 The FC126 strain was isolated from 23-week-old turkey flock that had a history 
of lymphoid tumors and when experimentally inoculated, it caused no disease in 
chickens (Witter et al., 1970).  Chickens vaccinated with FC126 survived 100% the JM 
strain challenge (Okazaki et al., 1970). Interestingly, cell free virus obtained by 
sonication of FC126 infected CEF also protected chickens against challenge with 
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virulent virus (Okazaki et al., 1970). It is noteworthy that cell free virus cannot be 
obtained with two other serotypes and thus, freeze-dried (lyophilized) vaccines are only 
available for FC126 strain.  
1.8.4. Protective synergism 
 Although the protective efficiency of SB-1 and HVT was good in chickens that 
lacked maternal antibodies, it was less efficient in chickens that had maternal antibodies. 
Interestingly, these chickens were protected better when they were vaccinated with both 
strains instead of one (Schat et al., 1982). In other words, the degree of protection by one 
vaccine is increased by the inclusion of a second vaccine.  Subsequently, this 
phenomenon was named as  “protective synergism” (Witter and Lee, 1984). 
1.9. MDV unique genes and their role in pathogenesis 
1.9.1. MDV phosphoprotein 38 (pp38) 
The pp38 gene, which codes for 290 aa long protein, is located in the BamHI-H 
fragment at the junction of UL and IRL regions (Cui et al., 1990). The pp38 antigen is 
expressed in MDV lymphoblastoid cell lines as well as in tumor samples (Cui et al., 
1990) and is essential for the maintenance of transformation phenotype of MSB-1 (Xie 
et al., 1996). These findings indicated a role for pp38 in transformation process. 
However, the expression of pp38 is restricted to early cytolytic phase of the MDV 
infection. Importantly, a direct role of pp38 only in the early cytolytic infection has been 
demonstrated by using a pp38-null MDV recombinant virus, which did not replicate well 
but still retained the ability to induce tumors in chickens, albeit at a lower level (Reddy 
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et al., 2002). Furthermore, MDV strains belonging to all three serotypes encode for the 
pp38, suggesting that it has no direct role in oncogenesis. 
1.9.2. Viral lipase (vLIP) 
The viral lipase (vLIP) is a 756 amino acid long protein with 26 % sequence 
identity to the α/β hydrolase fold of pancreatic lipase (Kamil et al., 2005). The vLIP 
gene, found in the genome of all three serotypes, is located in the UL region. The vLIP 
lacks enzymatic activity and is secreted (Kamil et al., 2005). Tumor incidences were 
reduced by 53% in chickens infected with MDV virus lacking vLIP while parental MDV 
caused tumors in 90% of chickens (Kamil et al., 2005). Therefore, vLIP could be 
involved in the MDV-induced oncogenesis, but not as a major determinant. 
1.9.3. vIL-8 
The vIL-8 gene is located within the BamHI-L fragment of MDV-1 genomes and 
encodes for 134 aa long chemokine that has high homology to human and chicken 
cellular IL-8 (Liu et al., 1999a; Parcells et al., 2001). This secreted protein attracts 
PBMC and not heterophils (Parcells et al., 2001). vIL-8 is expressed late in the infection 
and may play a role in lytic phase of MDV infection through recruiting target cells; 
however, it is not essential for viral replication, latency, tumor formation and virus 
transmission (Cui et al., 2004; Parcells et al., 2001). Interestingly, vIL contains a DKR 
motif instead of the ELR motif present in cellular counter that attracts heterophils. 
Recombinant MDV carrying DKR-to-ELR mutation functions similar to the parental 
MDV virus, indicating no disadvantage in pathogenesis for having DKR motif (Cui et 
al., 2004). 
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1.9.4. Viral telomerase RNA gene (vTR) 
In the course of analyzing the ends of the RB1B genome, a 443-bp long, a novel 
viral telomerase RNA gene (vTR) was discovered and its sequence was found to share 
88% identity with chicken telomerase RNA subunit gene (cTR) (Fragnet et al., 2003). To 
date, this is the only known TR of viral origin. The telomerase complex, which plays a 
role in the replication of telomere DNA, comprises of a protein subunit (TERT) with 
reverse transcriptase activity, and an RNA subunit (TR) containing a short, specific 
template for TERT. The vTR combines with cellular TERT to form a telomerase 
complex, which has been shown to be functional (Fragnet et al., 2003). When injected 
with a vTR-null MDV, the tumor incidence was reduced by 60 % in chickens when 
compared to wild type MDV, suggesting a role for vTR in oncogenesis (Trapp et al., 
2006); however, it may not be major determinant since a non-oncogenic MDV vaccine 
strain CVI988 also contains this gene. 
1.9.5. Meq 
The meq gene (MDV EcoQ fragment) located in the BamI2-BamQ2/EcoQ 
fragments within the repeat long regions was first identified based on a observation that 
the EcoQ transcripts are abundantly present in the MDV transformed T-cell lines such as 
RP1, RP4, and MSB1 as well as in tumors (Jones et al., 1992). Later, expression of Meq 
proteins was demonstrated in these cell lines (Liu et al., 1998).  
Meq is a 339 amino acid long protein; contains a DNA binding domain (1-128) 
with a basic-leucine zipper, similar in structure to c-jun/c-fos bZIP proteins, at its amino 
terminus and a transactivation domain (129-339) with two and half repeats of proline 
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rich sequences, closely resembles that of WT-1 (Wilm’s tumor suppressor protein), at its 
carboxy terminus (Jones et al., 1992; Qian et al., 1995) (Fig. 4). The C-terminal domain 
has transactivation properties, and at least one proline repeat is required for its full 
transactivation activity (Qian et al., 1995). Furthermore, the last 33 amino acids (307-
339), though not adequate, are critical for its function (Qian et al., 1995). As shown in 
WT-1, proline rich repeats in the transactivation domain of Meq also have 
transrepression functions when tested in its isolated form (Qian et al., 1995).  
 
 
 
Fig. 4. Structure of Meq. The structure of Meq is typical of a bZIP protein. It contains 
DNA binding domain (1-120) and transactivation/transrepression domain (121-339). The 
function of each region is indicated. 
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Meq has the ability to bind its own promoter, which contains two AP-1 like 
binding sequences. This binding, as well as transcription from the meq, promoter can be 
increased with the co-expression of c-jun (Qian et al., 1995). Thus, Meq has the ability 
to form heterodimers with c-jun, a major interacting partner in the cells. There is also 
evidence that Meq and c-jun colocalize in the cells (Liu et al., 1999a). Chimeric proteins, 
bZIP-Meq/TA-c-jun and bZIP-c-jun/TA-Meq, have similar properties as Meq and c-jun, 
suggesting that the bZIP and transactivation domains of these proteins can complement 
each other in the transformation process (Liu et al., 1999a). Meq/c-jun heterodimer 
preferentially binds cyclic AMP (CRE)-and 12-O-tetradecanoylphorbol 13-acetate 
responsive element (TRE)-like sequences, called MERE (Meq response element) I such 
as the one in the meq promoter (Qian et al., 1996). Thus, Meq/c-jun heterodimer has 
stronger activity on the meq promoter when compared to Meq/Meq and Jun/Jun 
homodimers. The sequence of MERE I is GAGTGATGAC(G)TCATC (TRE/CRE 
sequence is indicated in bold). On the other hand, Meq/Meq homodimer preferentially 
binds a consensus sequence ACACACA, called MERE II (Qian et al., 1996). Meq/Meq 
homodimers and not Meq/c-jun heterodimer suppress transcription of pp38/pp14, a 
bidirectional promoter located in the MDV-Ori (Levy et al., 2003b). By CHIP assay, 
Meq has been shown to bind MDV promoters such as meq , ICP4, gB, and gD, which 
contains MERE I sequence and MDV-Ori, which contains MERE II sequence (Levy et 
al., 2003b).  Furthermore, Meq/jun heterodimer also has the ability to bind AP-1 
containing chicken promoters such as IL-2. Though yet to be proven, presence of 
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potential RNA binding motif in the transactivation domain (315-SGQIYIQF-322) 
suggests that Meq also binds RNA besides DNA (Lee et al., 2003). 
Several studies have pointed out that Meq can interact with cellular proteins in 
addition to c-Jun. For example, Meq has been shown to interact with the putative 
tetramerization domain of chicken p53 via its basic region (54-127) (Brunovskis et al., 
1996). Additionally, Meq interacts with c-Fos, Jun-B, CREB, ATF-1, ATF-2, and ATF-
3. Presence of the RB-binding consensus (LXCXE) at the end of the ZIP domain 
suggests Meq can potentially interact with RB (Liu and Kung, 2000), but studies are 
warranted to prove this. 
Expression of Meq can be predominantly found in the nucleoplasm as well as the 
nucleolus during all phases of the cell cycle. Two basic signal sequences, BR1 (30-
RRKKRK-35) and BR2 (62-RRRKRNRDAARRRRRKQ-77), present in the N-terminus 
are required for Meq’s nuclear localization (Liu et al., 1997). While either BR1 and/or 
BR2 function as nuclear localization signals (NLS), BR2 is the sole nucleolar 
localization signal (NoLS). In addition, Meq can be found in the cytoplasm and 
colocalizes with CDK2 in the coiled bodies during S phase of the cell cycle (Liu et al., 
1999b). Whether Meq causes translocation of CDK2 in to the coiled bodies to cause 
disruption of the cell cycle remains to be explored. It is noteworthy that this 
colocalization causes phosphorylation by CDK2 of the serine residue at position 42 of 
Meq leading to its translocation into the cytoplasm (Liu et al., 1999b). Additional work 
points out that Meq can also be phosphorylated by PKA, PKC, and MAPK. Further, 
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colocalization of Meq with PCNA in the nucleoplasm has been reported suggesting a 
role for Meq in DNA replication (Liu and Kung, 2000). 
Meq is required for maintenance of the transformation state since induction of 
RNA antisense to meq in MSB-1, a MDV transformed cell line, results in reduced 
colony formation in soft agar assay (Xie et al., 1996). It has also been suggested that 
Meq cooperates with the proto-oncogene c-Myb in the maintenance of transformation 
phenotype of T9, a MDV transformed cell line that contains a Rous associated virus 
insertional activation of c-myb (Le Rouzic and Perbal, 1996). Further, transformed CD4 
cells carrying AV37 marker in chickens have been found to consistently express Meq 
(Ross et al., 1997).  
When overexpressed, Meq transforms immortalized rat fibroblasts (Rat-2) and 
immortal chicken fibroblasts (DF-1) (Levy et al., 2005; Liu et al., 1998). Thus far, Meq 
has not been shown to transform primary fibroblasts, and it causes sarcomas only in 5% 
of chickens when infected with replication defective retrovirus virus carrying meq. 
These findings suggest that Meq is a weak oncoprotein. Like Jun and Fos, Meq promotes 
growth of cells in the absence of serum and protects them against apoptosis inducing 
agents including TNF-α, C2-Ceramide, UV irradiation and serum starvation (Liu et al., 
1998). The anti-apoptotic function of Meq might be due its ability to increase bcl-2 
expression and to decrease bax expression (Liu et al., 1998). 
Recently, the function of Meq in chickens has been examined. The rMd5ΔMeq 
virus in which the meq genes were deleted failed to induce tumors, where as rMd5 virus 
that had intact meq genes caused tumors in susceptible chickens (Lupiani et al., 2004). 
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This study provided compelling evidence that Meq is essential for transformation of T 
lymphocytes. Additional evidence that Meq is a major MDV oncoprotein came from the 
studies of the pRB-1B-Ct20 virus with mutations in the meq gene that eliminated the 
interaction with C-terminal-binding protein (CtBP), which was nononcogenic in 
chickens (Brown et al., 2006). Meq interacts with CtBP through a motif located in the 
DNA binding domain (20-PLDLS-24).   
Recent evidence suggests that the Meq transforms via v-Jun pathway. These 
observations are: (1) morphology of Meq transformed DF-1 cells were similar to v-Jun 
transformed cells, (2) Meq protects DF-1 cells against apoptosis, (3) up-regulation of 
genes such as JTAP-1, JAC, and HB-EGF, implicated in v-Jun transformation process, 
and (4) Meq cooperates with c-Jun in the transformation of DF-1 cells (Levy et al., 
2005). 
In addition to the meq, at least three variants of the meq transcripts are reported 
in the literature: the L-meq, meq/vIL8 and Δmeq. The L- meq gene (1,185 bp) was first 
described in CVI988-infected CEF DNA (Lee et al., 2000b). This has an insertion of 
178-bp in the form of proline rich repeat and is absent in CEF infected with other MDV-
1 strains including GA, Md5, RB1B or MDV-2 strains including SB infected CEF. The 
L-meq gene can be found in spleen and PBMC collected from chickens infected with 
CVI988 and JM strains. Recently, this gene has been reported in two more MDV strains, 
CU-2 and BC-1 (Shamblin et al., 2004). When co-expressed, the L-Meq protein has been 
shown to decrease the transactivation function of Meq (Chang et al., 2002b). 
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The Meq/vIL8 protein, first identified as Meq-sp in MKT-1 and MSB-1 cell 
lines, is a 212 amino acid long splice variant of Meq (Peng and Shirazi, 1996; Peng et 
al., 1995). The first 100 amino acids of this protein are identical to Meq protein, where 
as the rest corresponds to receptor binding region of vIL8. This protein lacks 
transactivation domain and secretor signal of Meq and vIL8, respectively. The Meq/vIL8 
could function as a negative regulator of Meq since it is able to bind the meq promoter 
and is also able to interact with c-jun. Furthermore, Meq/vIl8 forms homodimers and 
localizes in the nucleus, nucleolus and coiled bodies, similar to Meq (Anobile et al., 
2006). 
Recently, another splice variant of meq, termed Δmeq, was found in MSB-1 cells 
and CEFs infected with Md5 (Okada et al., 2007). The first 99 amino acids at the N-
terminus of the Δmeq protein are identical to Meq, while the remaining 30 amino acids 
at the C-terminus are from a different reading frame and therefore of different sequence. 
This novel protein lacks the transactivation domain of Meq, has anti-apoptotic property, 
dimerizes with Meq and L-Meq and suppresses transcription by both Meq and L-Meq. 
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2. IN VITRO CHARACTERIZATION OF THE MEQ PROTEINS OF  
MAREK’S DISEASE VIRUS VACCINE STRAIN CVI988 ∗ 
2.1. Introduction 
Gallid herpesvirus 2 (GaHV-2), commonly known as Marek’s disease virus 
serotype 1 (MDV-1), causes Marek’s disease (MD) in chickens. MDV-1 is classified in 
the genus Mardivirus along with two other non-oncogenic poultry viruses, Gallid 
herpesvirus 3 (GaHV-3 or MDV serotype 2) and Meleagrid herpesvirus 1 (MeHV-1, 
MDV serotype 3 or Turkey herpesvirus) in the subfamily Alphaherpesvirinae. MD is 
characterized by T cell tumors, partial or complete paralysis of legs and wings, 
immunosuppression, skin leukosis, depression, and death (Calnek, 2001; Marek, 1907; 
Pappenheimer et al., 1929). MDV is prevalent in commercial poultry due to its high 
infectivity and long-term survivability outside its host and is also responsible for 
significant economic losses worldwide. Based on the severity of the disease in 
vaccinated chickens, MDV-1 strains in North America are classified as mild (m), 
virulent (v), very virulent (vv) and very virulent plus (vv+) (Witter, 1997). MDV 
replicates in B and T lymphocytes during early cytolytic infection and subsequently 
establishes latency, a common feature of herpesvirus infections, in T lymphocytes. The 
virus transforms activated T lymphocytes that infiltrate several visceral organs, 
peripheral nerves, and skin as early as 3 weeks post infection (Calnek, 2001). 
∗Reprinted with permission from “In vitro characterization of the Meq oncoproteins of 
Marek’s disease virus vaccine strain CVI988” by Ajithdoss, D.K., Reddy, S.M., 
Suchodolski, P.F., Lee, L.F., Kung, H.J. and Lupiani, B, 2009. Virus Research, in press, 
Copyright (2009) by Elsevier B.V. 
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The MDV genome consists of a unique long (UL), and a unique short (US) region 
flanked by inverted repeat regions, commonly referred to as terminal and internal repeats 
(TRL, IRL, IRS and TRS) and the sizes vary depending upon the strain; HVT strain FC-
126 (159,160-bp)(Afonso et al., 2001), MDV-2 strain HPRS24 (164,270-bp) (Izumiya et 
al., 2001), MDV-1 strain GA (174,000-bp) (Lee et al., 2000a), and MDV-1 strain Md5 
(177,874 bp) (Lee et al., 2000a; Tulman et al., 2000). The organization of the MDV 
genome resembles that of human herpesvirus 1 (HSV-1) with a co-linear organization of 
genes in both the unique long and unique short regions. MDV-1 specific genes, such as 
vIL-8 (Cui et al., 2004; Parcells et al., 2001), viral telomerase RNA (vTR) (Fragnet et 
al., 2003), viral lipase (Kamil et al., 2005), meq (Brown et al., 2006; Lupiani et al., 
2004), and pp38 (Reddy et al., 2002), have been  implicated in pathogenesis. Only 
MDV-1 strains are oncogenic and code for a unique basic leucine zipper (bZIP) protein, 
Meq (MDV EcoRI Q fragment). Two identical copies of the meq oncogene are present 
in the repeat long regions (TRL, and IRL) and is commonly expressed in MDV 
lymphoma cells (Jones et al., 1992). Meq has been shown to transform fibroblast cell 
lines (Rat-2 and DF-1 cells), protect fibroblasts against serum starvation and apoptosis 
inducers, as well as promote proliferation of cells, all characteristics of oncoproteins 
(Levy et al., 2003a; Levy et al., 2005; Liu et al., 1998). More importantly, recent work in 
our lab with a MDV mutant virus lacking both copies of meq has conclusively shown 
that Meq is required for transformation of T lymphocytes, but is not necessary for early 
viral replication (Lupiani et al., 2004).  
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Meq is 339 amino acids long and contains a basic amino acid rich DNA binding 
domain at the amino terminus (1-120) and a proline rich transactivation domain at the 
carboxy terminus (121-339). Meq also contains both nucleus and nucleolus localization 
signals (Liu et al., 1997) and co-localizes with Cdk2 in coiled bodies (Liu et al., 1999b)., 
Like other bZIP proteins, Meq posseses transactivation activity and is capable of 
forming homodimers with itself as well as heterodimers with other bZIP proteins such as 
c-Jun. Meq homodimers have been shown to repress MDV early promoters such as pp38 
and pp14 while Meq/c-Jun heterodimers have been reported to activate the meq 
promoter (Levy et al., 2003b). Meq, like v-Jun, has also been shown to increase 
transcription of genes involved in growth and anti-apoptosis, suggesting the Jun pathway 
is involved in MDV transformation (Levy et al., 2005). In addition, Meq has been shown 
to interact with a cellular co-repressor, C-terminal-binding protein (CtBP), and this 
interaction is essential for MDV oncogenesis (Brown et al., 2006). 
MD vaccines are effective in the prevention of tumor development but not 
infection.  Studies have shown that field isolates continuously evolve towards greater 
virulence (Witter, 1997), and vaccination has been suggested as one of the driving forces 
in this evolution (Schat and Baranowski, 2007; Witter, 1998). Consequently, current 
vaccines may not be effective against MD in the near future. Understanding the 
molecular mechanisms of T cell transformation by this virus is critical for designing the 
next generation of vaccines against these evolving MD viruses. Several researchers have 
explored the use of cell culture attenuated MDV-1 strains as vaccines with little success 
(Churchill et al., 1969a; Nazerian, 1970; Rispens et al., 1972; Vielitz and Landgraf, 
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1971; Witter, 1982). Currently, attenuated CVI988/Rispens MDV-1 strain is used as a 
vaccine in the USA, and in Europe (Baigent et al., 2006) and offers best protection. 
Interestingly, although attenuated vaccine strains of CVI988/Rispens encode and express 
Meq, they are non-oncogenic in chickens. Additionally, CVI988/Rispens encode and 
expresses a longer form of Meq (LMeq, 398 amino acids), which contains 59 amino 
acids in the form of a proline rich repeat in the transactivation domain (Chang et al., 
2002a). Comparison of the predicted amino acid sequences of Meq from the very 
virulent strain Md5 and the vaccine strain CVI988/Rispens revealed 2 and 4 amino acid 
differences in the DNA binding and transactivation domains, respectively (Shamblin et 
al., 2004) (Fig. 5); however, the significance of these differences is currently unknown.  
The objective of the current study was to determine how these amino acid 
differences affect the in vitro transformation and transactivation properties of Meq 
proteins expressed by CVI988/Rispens. Our results indicate Meq proteins from both 
very virulent Md5 and vaccine CVI988/Rispens strains were capable of transforming 
Rat-2 and NIH 3T3 cells in vitro. Only Md5-Meq but not CVI Meq proteins 
transactivated the Md5-meq promoter in a dose dependent manner. Interestingly, in the 
presence of chicken c-Jun (CK-Jun), CVI-Meq and CVI-LMeq also activated the meq 
promoter. Chimeric Meq proteins in which DNA binding and transactivation domains 
were exchanged between Md5 Meq and CVI Meq, significantly transactivated the meq 
promoter. Residues at positions 71 (S) and 320 (T) in Md5 Meq protein were found to be 
critical for its function. All three Meq proteins suppressed expression from the 
bidirectional promoter of the MDV (pp38/pp14) and activated MDV late promoter gB;  
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Fig. 5. Structure of the Meq proteins of Md5 and CVI988/Rispens strains.  Meq contains 
an amino-terminal DNA binding domain and a carboxy-terminal transactivation domain. 
The DNA binding domain contains localization signals for nucleus and nucleolus and a 
leucine zipper for dimerization with itself and other bZIP proteins. The transactivation 
domain is rich in proline and is essential for its transactivation function. CVI-Meq 
proteins have 2 amino acid differences in the DNA binding domain and 4 amino acids 
differences in the transactivation domain when compared to Md5-Meq. In addition, CVI-
LMeq has a 59 amino acid insertion that is rich in proline. 
 
however, in general, higher activation was obtained with Md5-Meq. Similar results were 
obtained for cellular MMP-3, and Bcl-2 promoters. Our findings indicate Meq proteins 
from CVI988/Rispens vaccine strain differ from Md5 Meq protein in transactivation 
activity but not in in vitro transformation properties. Based on these results, the lack of 
oncogenicity of CVI988/Rispens in chickens may be more related to transactivation 
potential than fibroblast-transforming ability of Meq protein. 
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2.2. Materials and methods 
2.2.1. Cell culture 
DF-1, a chicken embryo fibroblast continuous cell line, was maintained in 
Leibowitz-McCoy media supplemented with 4% fetal bovine serum (FBS) and 
penicillin-streptomycin at 37°C.  Cell lines 293T (human embryonic kidney cells 
containing SV40 T antigen), NIH 3T3 (mouse embryonic fibroblast) and Rat-2 (rat 
embryo) were cultured in Dulbecco’s minimum essential medium (DMEM) 
supplemented with 10% FBS and penicillin-streptomycin at 37°C. 
2.2.2. Cloning of meq and chicken c-jun (CK-jun) genes 
The open reading frames of meq gene from Md5 (Md5-meq) and CVI988/Ripens 
(CVI-meq and CVI-Lmeq) were PCR amplified from viral DNA using primers (SR1118 
forward: 5’-GATCCCGGGGAGATGTCTCAGG AGCCAGAG-3’) and (SR1135 
reverse: 5’- GATCCCGGGTCAGGGTCTCCCGTCA CCTGGAAACC-3’) containing 
SmaI sites (indicated in bold) and cloned into pZero vector (Invitrogen, Carlsbad, CA). 
Following sequencing, all meq genes were subcloned into the PmeI site of pcDNA 3.1 
(Invitrogen, Carlsbad, CA) to generate pMd5-Meq, pCVI-Meq and pCVI-LMeq vectors 
for transactivation assays and into SnaBI site of pBabe vector (kind gift from Dr. David 
Everly, University of North Carolina) to generate pB-Md5-Meq, pB-CVI-Meq and pB-
CVI-LMeq vectors for transformation assays.  
Three chimeric Meq protein expression vectors [pMd5-CVI-Meq (DNA binding 
domain of Md5-Meq protein and transactivation domain of CVI-Meq protein), pCVI-
Md5-Meq (DNA binding domain of CVI-Meq protein and transactivation domain of 
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Md5-Meq protein), and pMd5-CVI-L (DNA binding domain of Md5-Meq protein and 
transactivation domain of CVI-LMeq protein)] were constructed by exchanging DNA 
binding domains. Briefly, pMd5-CVI-Meq was constructed as follows: the KpnI 
fragment region of pCR2.1-EcoQ-CVI was replaced with the KpnI fragment derived 
from pCR2.1-EcoQ-Md5 (MDV EcoQ fragment contains the meq gene). The chimeric 
Md5-CVI- Meq gene was then PCR amplified using SR1118 and SR1135 primers and 
cloned in pZero vector. Following digestion with SmaI, the Md5/CVI meq gene was 
ligated to pcDNA 3.1 vector cut with PmeI. The resulting construct was designated as 
pMd5-CVI-Meq.  The pCVI-Md5-Meq and pMd5-CVI-L chimeric vectors were 
constructed using the same strategy as for the pMd5-CVI-Meq and the accuracy of all 
the chimeric genes was confirmed by sequencing of these constructs. 
Six single amino acid Md5-Meq mutants (A71S, K77E, A217P, V283A, T320I 
and T326I) were constructed using the QuikchangeTM site-directed mutagenesis kit 
(Stratagene, La Jolla, CA). Residues in Md5-Meq and corresponding residues in CVI-
Meq are indicated in bold and underlined, respectively.  All mutations were verified by 
DNA sequencing. 
The chicken c-jun gene (CK-jun) was cloned as follows: RNA was isolated from 
DF-1 cells using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and cDNA of CK-jun 
was made using gene specific primers (BL1227 forward: 5’ GACCCGGGATGAGTCA 
AAGATGGAGCCTAC-3’ and BL1228 reverse: 5’GACCCGG GTCAAAACGTTTGC 
AACTGTTGTG-3’) containing SmaI sites (indicated in bold). A full-length CK-jun 
 33 
cDNA was cloned into the PmeI site of pcDNA following confirmation by sequencing 
and the resultant recombinant plasmid was named pCK-Jun. 
2.2.3. Retrovirus production and transduction 
Replication incompetent murine retroviruses carrying the meq genes of Md5 and 
CVI988/Rispens were constructed as previously described (Everly et al., 2004). Briefly, 
5 x 106 293T cells were seeded in a 75 cm2 tissue culture flask one day prior to 
transfection and cultured overnight at 37°C. Using siPORT-XP-1 transfection reagent 
(Ambion, Austin, TX), 6 µg of control pBabe, pB-Md5-Meq, pB-CVI-Meq, or pB-CVI-
Meq-L; 6 µg of pG1-VSV-G (VSV-G expression vector); and 6 µg of pGPZ9 (murine 
leukemia virus Gag-Pol expression vector) were triple-transfected into 293T cells. The 
culture media was changed the following day and cells were transferred to 33°C. Culture 
supernatants were collected 48 hr post transfection and centrifuged at 1,000 xg for 10 
minutes. NIH 3T3 cells and Rat-2 cells were transduced overnight with clarified culture 
supernatants in the presence of polybrene (8 µg/ml) (Sigma, St Louis, MO). Cell lines 
were established by selecting transduced cells with puromycin (4 µg/ml) (InvivoGen, 
San Diego, CA) and later maintained in DMEM supplemented with 10% FBS and 
puromycin (2 µg/ml).  
2.2.4. Immunofluorescence 
Immunofluorescence was performed as previously described with modifications 
(Lee et al., 2003). Briefly, transduced cells were washed with PBS and fixed with 
ethanol:acetone solution (6:4) at 37°C for 10 min. After removing fixing solution, the 
cells were air-dried, and subsequently incubated with anti-Meq rabbit polyclonal serum 
 34 
(1:200) for 1 hr at 37°C. Following three washes with PBS, cells were incubated with 
goat anti-rabbit FITC labeled secondary antibodies (KPL, Gaithersburg, MD) for 1 hr. 
Cells were then washed 3 times with PBS and examined under a fluorescence 
microscope. 
2.2.5. Western blot analysis 
Meq transformed Rat-2 or NIH 3T3 cell lines (0.5 million cells) were mixed with 
SDS-PAGE sample buffer and heated at 95 °C for 5 min. Samples were size-separated 
by electrophoresis on a 12% SDS-containing polyacrylamide gel followed by transfer of 
proteins onto a nitrocellulose membrane. After transferring, the membrane was 
incubated at room temperature for 30 min with blocking buffer (Invitrogen, Carlsbad, 
CA) and subsequently incubated with rabbit anti-Meq (diluted 1:2000) for 1 hr at room 
temperature (Lee et al., 2003). The membrane was washed three times with PBST (PBS 
plus 0.1% Tween-20), 15 min each and then incubated with anti-rabbit HRP-conjugated 
antibody (1:2500) for 1 hr at room temperature. Following three 15 min washes with 
PBST, the membrane was incubated with TMB membrane peroxidase substrate system 
according to manufacturer’s instructions (KPL, Gaithersburg, MD). 
DF-1 cells or DF-1 cells transfected with pCK-Jun vector were processed for c-
jun expression by Western blot analysis as described above. The primary antibody, 
rabbit anti-c-Jun, was purchased from Upstate Biotechnology (Lake Placid, NY) and 
used at a 1:1000 dilution. 
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2.2.6.  In vitro transformation assays 
For focus formation assay, 4 x 106 puromycin selected Rat-2 or NIH 3T3 cells 
were seeded in 100 cm2 dishes and allowed to reach confluency after which they were 
maintained in DMEM supplemented with 0.5% FBS (Rat-2 cells) or 3% FBS (NIH3T3 
cells) for 3-4 weeks. For soft agar assay, 5 X 103 puromycin selected Rat-2 or NIH 3T3 
cells in 0.3 % agar in DMEM supplemented with 10% FBS per well were seeded on a 
layer of 0.6 % agar in 6 well plates. Cells were cultured for 3-4 weeks, after which foci 
were stained with crystal violet and photographed. At least three independent 
experiments were performed in triplicate. 
2.2.7. Cloning of viral and cellular promoters 
The Md5-meq promoter (nucleotides -355 to -1) was amplified from viral DNA 
as previously described (Chang et al., 2002b) and cloned upstream of the firefly 
Luciferase gene in the pGL3 vector (Promega, Madison, WI). MDV early promoters 
(pp38 and pp14) in pGL2 vector have been previously described (Levy et al., 2003b). 
The pGL2-3XOri vector containing 5’ to 3’ three tandem copies of the MDV Ori 
sequence (TGC TCA TTT GCA TAC ACA TCA CGT GAT AGT) (Meq binding 
sequence is indicated in bold), present in the pp38/pp14 bidirectional promoter, was 
constructed following self-ligation of three MDV Ori sequences and cloning into the 
pGL-2 vector. Md5 gB promoter (nucleotides -661 to -20 upstream of the translation 
initiation site) (Sonoda et al., 2000) was amplified from Md5 viral DNA using primers 
(BL1339 forward: 5’-TCAGATCTC AAGTCTCACTC ACA AA-3’ and BL1340 
reverse: 5’-TCAGATCT GCTGTTCATAAATT GTGT-3’) containing BglII sites 
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(indicated in bold) and following sequencing, the gB promoter was cloned into the BglII 
site of the pGL3 vector. Similarly, chicken Bcl-2 promoter (nucleotides -312 to -1 
upstream of the translation initiation site) described elsewhere (Lesault et al., 2002)  was 
cloned into the pGL3 vector following amplification from chicken lymphocyte DNA 
using primers (BL1338 forward: 5’-TCA GATCTGACAGCCAGGAGGAAGCG-3’ 
and BL1340 reverse: 5’-TCAGATCTTGGG AGGGGGAGAGGAAG-3’) containing 
BglII sites (indicated in bold). The cellular promoter MMP-3 (nucleotides -2264 to +37) 
in pGL3 vector (Kwak et al., 2007) was generously provided by Dr. Weston Porter 
(Texas A&M University).  
2 2.8. Luciferase reporter assays 
For the luciferase assay, DF-1 cells were seeded in 12-well plates (105 cells per 
well) a day before transfection. The following day, 125-500 ng of pcDNA vector, pMd5-
Meq, pCVI-Meq, or pCVI-LMeq were transfected along with 250 ng of the indicated 
promoter reporter vectors using siPORT-XP-1 transfection reagent (Ambion, Austin, 
TX) according to the manufacturer’s instructions. The total amount of DNA transfected 
was kept constant (750 ng) by supplementing test vectors with appropriate amounts of 
control pcDNA expression vector. Cells were lysed 24 hr later using lysis buffer 
(Promega, Madison, WI) and firefly luciferase activity was measured using a 
luminometer (BioTek Instruments, Winooski, VT). Protein concentration for each 
transfected sample was measured using the Bradford assay (Bio-Rad, Hercules, CA) and 
luciferase activity was normalized to protein concentration as previously described 
(Papin et al., 2003). Fold increase in luciferase activity of the different Meq expressing 
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vectors relative to pCDNA control vector were expressed as the mean ± standard error of 
three independent experiments performed in triplicate. Results were analyzed using one-
way ANOVA followed by Tukey HSD test in SPSS®, Version 14.0 software (SPSS Inc., 
Chicago, IL, USA). For all analysis, P ≤ 0.05 was considered statistically significant. 
2.2.9. Chromatin immunoprecipitation assay (ChIP) 
DF-1 cells (106 cells per well) were seeded on a 100 mm plate were transfected 
with 3µg of pGL3-meq promoter together with 3µg of either pMd5-Meq, pCVI-Meq, 
pCVI-LMeq or pcDNA control vector using siPORT-XP-1 transfection reagent 
(Ambion, Austin, TX) as per manufacturer’s instructions. In parallel experiments, pCK-
Jun was included in the transfection mix. The ChIP assay was performed as previously 
described (Metz et al., 2006). Briefly, 24 hr following transfection, cells were fixed in 
1% formaldehyde for 15 min at 37°C and glycine (125 mM final concentration) was 
added to stop the cross-linking reaction. Cells were washed three times with PBS by 
centrifuging at 913 xg for 4 min and following the last wash, the cell pellet was 
resuspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8.1).  Cells 
were sonicated 10 times for 10 sec with 3 min cooling on ice in between pulses in order 
to shear the cross-linked chromatin which would result in an average DNA fragment 
length of 200-1000 bp. Sonicated cells were centrifuged at   15,700 xg for 10 min, and 
soluble cross-linked chromatin was collected and diluted in ChIP dilution buffer (0.01% 
SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, 167 mM NaCl) containing 
protease inhibitor cocktail.  Diluted cross-linked chromatin was subsequently precleared 
with protein G-agarose beads and blocked with sonicated salmon sperm DNA for 30 min 
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at 4°C. The protein G-agarose beads were removed by centrifugation and an aliquot of 
supernatant was collected as “input DNA”. The remaining chromatin was 
immunoprecipitated with anti-Meq rabbit polyclonal serum (Lee et al., 2003; Levy et al., 
2003b) or control rabbit IgG antibody at 4°C overnight. The following day, the reaction 
mixture was incubated with protein G-agarose beads at 4°C for 1 h and centrifuged at 
100 xg for 1 min. Recovered beads were washed once with low salt buffer (0.1% SDS, 
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 150 mM NaCl), once with high salt 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, 500 mM NaCl), 
once with LiCl buffer (0.25 M LiCl, 1% NP40, 1% deoxycholic acid, sodium salt, 1mM 
EDTA and 10 mM Tris), and twice with TE buffer (10 mM Tris-HCl, 1 mM EDTA). 
Immunoprecipitated chromatin was subsequently eluted with elution buffer (1% SDS, 
0.1M NaHCO3).The anti-Meq and IgG antibody immunoprecipitated as well as ”input 
DNA” samples were incubated at 65°C for 4 hr in order to reverse the cross-linking. 
Samples were treated with proteinase K for 1 hr at 45°C, DNA precipitated with 2.5 
volumes of 100% ethanol, and resuspended in 100 µl of TE buffer. DNA was purified 
using the QIAquick PCR purification kit (Qiagen, Valencia, CA) and eluted in 50 µl of 
sterile water. Processed samples were analyzed by standard PCR with pGL3 vector 
specific primers (SR3391 forward: 5’- GCTCTCCATCAAAACA AAAC-3’ and 
SR3393 reverse: 5’-GTGGCTTTACCA ACAGTACC-3’), which amplify the meq 
promoter cloned into the pGL3 vector. 
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2.3. Results 
2.3.1. Md5-Meq, CVI-Meq and CVI-LMeq proteins transform fibroblasts 
 Previous work in our laboratory has demonstrated that deletion of the meq gene 
from Md5 inhibited T cell tumor development in chickens confirming a direct role in 
MDV oncogenesis (Lupiani et al., 2004). Comparison of the predicted amino acid 
sequences of CVI-Meq and CVI-LMeq from the vaccine strain CVI988/Rispens with the 
Meq protein of the very virulent Md5 strain revealed two amino acid differences in the 
DNA binding domain (positions 71, and 77) and four amino acid differences in the 
transactivation domain (positions 217, 283, 320, and, 326) (Fig. 5). Additionally, CVI-
LMeq had a 59 amino acid insertion corresponding to the proline rich repeat region (Fig. 
5). Since attenuated CVI988/Rispens is non-oncogenic in chickens, CVI-Meq and CVI-
LMeq were evaluated for transformation capabilities in vitro. Rat-2 and NIH3T3 cell 
lines expressing Md5-Meq, CVI-Meq, and CVI-LMeq proteins were developed using a 
murine retrovirus system. Integration of the murine retrovirus expression vector in these 
cell lines was confirmed by PCR and transcription of the meq genes was analyzed by 
RT-PCR using gene specific primers (data not shown). Expression of all three Meq 
proteins in transduced and selected cell lines was confirmed by Western blot (Fig. 6A) 
and immunofluorescence (Fig. 6B) assays. Both cell lines expressed Meq abundantly, 
predominantly in the nucleus. Rat-2 cells expressing all three Meq proteins formed foci 
only when grown under low serum conditions (0.5%) (Fig. 7). NIH 3T3 cell lines 
expressing all three Meq proteins formed foci when grown with 3% serum (Fig. 7). Rat-
2 cells and NIH3T3 cells expressing all three Meq proteins in anchorage independent  
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Fig. 6. Meq expression in cell lines. Six microgram of each of three plasmids (pBabe 
control vector or pBabe expressing Md5-Meq, CVI-Meq or CVI-LMeq proteins, pCMV-
Gag-Pol and pCMV-VSV-G) were transfected into 293T cells and the supernatant 
containing replication incompetent virus was collected 48 hr post transfection. The 
clarified media was used to transduce Rat-2 or NIH3T3 cells. Following puromycin 
selection, the expression of Meq under the control of the viral LTR was confirmed in 
both Rat-2 and NIH3T3 cells by Western blot (A). (1) pBabe empty vector, (2) pB-Md5 
Meq, (3) pB-CVI-LMeq, and (4) pB-CVI Meq. Expression of Meq in these cell lines 
were also confirmed by immunoflurosence (B) using Meq specific rabbit polyclonal 
sera. 
 41 
 
 
Fig. 7. Md5-Meq, CVI-Meq and CVI-Meq-L transform both Rat-2 and NIH3T3 cell 
lines. Puromycin selected Rat-2 and NIH 3T3 cells expressing Meq proteins were tested 
for transformation phenotype in two assays: focus and soft agar. Rat-2 cells expressing 
Meq proteins formed foci when grown under 0.5% serum and NIH3T3 cells expressing 
Meq proteins formed foci in 3% serum conditions. Both cell lines expressing Meq 
proteins formed colonies in soft agar under 10% serum conditions. Foci and soft agar 
colonies were stained with crystal violet and photographed. Results presented here are 
representative of three independent experiments.  
 
growth formed colonies under 10% serum conditions (Fig. 7). Fewer background 
colonies due to control pBabe vector were observed with NIH3T3 cells when compared 
to Rat-2 cells in the soft agar assay. Our results indicate that Md5-Meq, CVI-Meq, and 
CVI-LMeq proteins are able to transform fibroblasts in vitro despite the amino acid 
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differences found in the DNA binding and transactivation domains. 
2.3.2. Md5 Meq is a potent transactivator of its own promoter 
 Earlier studies have shown that Meq is a transcriptional activator of its own 
promoter (Levy et al., 2003b; Qian et al., 1995). Therefore, we wanted to determine if 
the Meq proteins of CVI988/Rispens have transactivation functions similar to or 
different from Md5-Meq on the meq promoter. Md5-meq, CVI-meq and CVI-Lmeq were 
cloned into the pcDNA eukaryotic expression vector, and the expression of Meq in DF-1 
cells was confirmed by immunofluorescence (data not shown). DF-1 cells were co-
transfected with pGL3-meq promoter and pcDNA vector coding one of the three Meq 
proteins or without any insert. In our preliminary experiments, Meq proteins, expressed 
from pcDNA vector, influenced the expression of renilla luciferase from pRL-SV40 
(normalizing control), probably due to Meq binding to AP-1 sites in SV40 promoter, 
causing errors in the analysis of the results as previously reported (Huszar et al., 2001). 
To address this problem, we normalized the luciferase values to the total protein 
concentration of the cell lysates and expressed the results as fold activation relative to 
the vector control (Papin et al., 2003). 
 As shown in Fig. 8A, only Md5-Meq activated the Md5-meq promoter in a dose 
dependent manner while CVI-Meq and CVI-LMeq had no effect (Fig. 8A). Md5-Meq 
driven activation of the meq promoter was statistically significant compared to the 
control vector and CVI-Meq expressing vectors. These data indicate that Md5- and CVI-
Meq proteins differ in their ability to transactivate their own promoter.  
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Fig. 8. Md5-Meq is a potent transactivator of its own promoter. (A) Effect of Meq 
proteins on its own promoter. The pGL3-meqpromoter construct (250 ng) was co-
transfected into DF-1 cells along with 125-500 ng of pcDNA or pcDNA expressing 
Md5-Meq, CVI-Meq or CVI-LMeq and 24 hr post-transfection luciferase activity was 
measured. The luciferase values were normalized to total protein concentration and fold 
activation relative to control pCDNA vector was used to create the graph. The 
experiment was done three times in triplicates. Error bars indicate SEM. (B) Expression 
of c-jun. Expression of c-jun from pCK-Jun vector (lane 1) and untransfected DF-1 cells 
(lane 2) was examined by Western blot using antisera against c-jun. (C) Transactivation 
of Meq in the presence of over expressed c-jun. Control vector or vectors expressing 
different Meq proteins (500 ng) were co-transfected along with pGL3-meq promoter 
reporter vector (250 ng) into DF-1 cells. Simultaneously, 0-500 ng of pCK-jun was 
transfected for a dose response assay. Luciferase activity was measured 24 hr following 
transfection. Fold activation was calculated relative to control vector. The experiment 
was done three times in triplicates. Error bars indicate SEM.  (D) Transrepression of 
Md5-Meq when co-expressed with CVI-Meq or CVI-Meq-L. Five hundred ng of pMd5-
Meq was co-transfected along with 0-500 ng of pCVI-Meq or pCVI-LMeq long in DF-1 
cells together with pGL3-meq promoter (250 ng) and 24 hr post transfection luciferase 
activity was measured. Values were expressed as fold activation relative to pcDNA 
vector. The luciferase activity of the control vector was assigned a value of 1.  The 
experiment was done three times in triplicates. Error bars indicate SEM. 
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Fig. 8. Continued 
 
Previous studies have shown c-Jun to be a major interacting bZIP protein for 
Meq and Meq/c-Jun interaction has been shown to increase the DNA binding activity of 
Meq to the AP-1 like sequences present in the meq promoter (Levy et al., 2003b). To test 
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whether CVI-Meq and CVI-LMeq are able to activate the meq promoter in the presence 
of CK-Jun, a luciferase assay was performed with triple-transfections of pGL3-meq 
promoter, pCK-Jun, and pcDNA vector expressing one of the three Meq proteins or  
control vector into DF-1 cells. Over expression of c-jun from pCK-Jun vector was 
confirmed by Western blot analysis (Fig. 8B). The results presented in Fig. 8C indicate 
that CK-Jun alone did not activate the meq promoter in the absence of Meq. Significant 
activation of the meq promoter with Md5-Meq was observed with increasing 
concentrations of transfected pCK-Jun. Likewise, both CVI-Meq, and CVI-LMeq 
activated the meq promoter in a dose dependent manner in the presence of tranfected 
pCK-Jun (Fig. 8C). Therefore, cotransfection with pCK-Jun is essential for CVI-Meq 
proteins but not for Md5-Meq to activate their own promoter.  
Because CVI-Meq proteins could not activate their own promoter and thus could 
interfere with the functions of Md5-Meq in case of mixed infection of CVI988/Rispens 
and Md5 viruses, we chose to investigate the transactivation function of Md5-Meq in the 
presence of CVI-Meq proteins. DF-1 cells were triple-transfected with pGL3-meq 
promoter, pMd5-Meq (500 ng), and increasing amounts of pCVI-Meq or pCVI-LMeq 
vectors (0-500 ng). Cells were collected 24 hr following transfection and lysed in order 
to determine luciferase activity. Our results show that both CVI-Meq and CVI-LMeq 
decreased the Md5-Meq mediated activation of the meq promoter in a dose-dependent 
manner (Fig. 8D). These data indicate CVI-Meq proteins could interfere with the 
expression of Md5-Meq in case of a mixed infection of pathogenic and CVI988/Rispens 
vaccines in chickens. 
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Taken together, the above results show CVI-Meq proteins activate the Md5 meq 
promoter only in the presence of CK-Jun, while Md5-Meq activates its own promoter 
both in the presence or absence of over-expressed CK-Jun. Furthermore, the 
transactivation function of Md5-Meq is suppressed by CVI-Meq proteins in a dose 
dependent manner. 
2.3.3. All three Meq proteins bind the meq promoter 
Because of the observation that CVI-Meq proteins could not transactivate their 
own promoter in the absence of CK-Jun, we wanted to test whether both CVI-Meq 
proteins are able to bind the meq promoter and whether this binding requires CK-Jun. 
DF-1 cells were transiently transfected with pGL3-meq promoter and pcDNA vector 
control or vectors expressing Md5-Meq, CVI-Meq, or CVI-LMeq in the presence or 
absence of pCK-Jun vector. Cells were collected 24 hr post transfection and processed 
for ChIP assay using anti-Meq polyclonal rabbit serum. “Input DNA” samples and all 
immunoprecipitates were PCR amplified using primers designed based on sequences 
external to the Md5-meq promoter in the pGL3 vector. As shown in Fig. 9, all three Meq 
proteins examined bind the Md5-meq promoter in the absence (Fig. 9A) or presence 
(Fig. 9B) of co-expressed CK-Jun. Amplification for the pcDNA vector control was 
observed in the “Input DNA” but not in the Meq immunoprecipitated sample, indicating 
that the bands observed in the Meq transfected samples were obtained by specific 
immunoprecipitation of Meq bound to the meq promoter. Samples immunoprecipitated 
with IgG control antibody were negative thereby confirming the specificity of the Meq 
antibodies. 
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Fig. 9. Md5-Meq and CVI-Meq proteins bind the meq promoter both in the presence or 
absence of c-Jun. DF-1 cells were transfected with pGL3-meq promoter, and one of 
pcDNA Meq expression or control vector in the absence (A) or presence (B) of pCK-
Jun. Cells were harvested and processed for ChIP assay as described in materials and 
methods. Input, rabbit IgG serum immunoprecipitated, and anti-Meq serum 
immunoprecipitated DNA were PCR amplified using pGL3 vector specific primers. 
Lane 1, Control vector; lane 2, pMd5-Meq; lane 3; pCVI-Meq; lane 4, pCVI-LMeq. 
 
These findings indicate that the amino acid differences observed in the DNA 
binding domain of CVI-Meq proteins do not affect DNA binding activity. 
2.3.4. Chimeric Meq proteins activate the meq promoter 
Since Meq proteins of CVI988 strain did not activate the meq promoter, we 
constructed chimeric Meq proteins by exchanging DNA binding domains among the 
three Meq proteins to better understand the role of the DNA binding domain and 
transactivation domain in transactivation. Each of the three chimeric constructs (pMd5-
CVI-Meq, pCVI-Md5-Meq, and pMd5-CVI-L) was transfected along with pGL3-meq 
promoter into DF-1 cells and luciferase activity determined 24 hr post transfection. All 
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three chimeric Meq proteins significantly increased the meq promoter activity compared 
to control vector and CVI-Meq proteins expressing vectors, although to a significantly 
lower level than did parental Md5-Meq protein (Fig. 10A). We conclude from these 
results that neither domain of the Md5-Meq protein is capable of fully restoring the 
transcriptional activity of CVI-Meq proteins, therefore both domains are required for 
maximum transactivation function of the Md5-Meq protein.  
2.3.5. Residues at 71 and 320 of Md5-Meq protein play a role in transactivation 
As shown in Fig. 5, Md5-Meq differs from CVI-Meq protein by six amino acid 
residues, two in the DNA binding domain and four in the transactivation domain. In 
order to determine the role of these residues in the transactivation activity of Meq, we 
used site-directed mutagenesis to generate six Md5-Meq mutants, in which one single 
amino acid had been replaced with that of CVI-Meq. Transfection of DF-1 cells with 
each of these six mutants (A71S, K77E, A217P, V283A, T320I and T326I) together with 
the pGL3-meq promoter was performed and cells were collected for assessing luciferase 
activity. Mutations at residues 77, 217, 283 and 326 did not significantly affect the 
ability of Md5-Meq protein to transactivate the Md5 meq promoter (Fig. 10B). In 
contrast, like CVI-Meq proteins, Md5-Meq mutants A71S and T320I, failed to 
transactivate the meq promoter (Fig. 10B). These data indicate alanine at position 71 and 
threonine at position 320 are important for Md5-Meq transactivation of its own 
promoter. 
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Fig. 10. Transactivation of the meq promoter by chimeric Meq proteins and Meq single 
amino acid mutants. DF-1 cells were co-transfected with either 250 ng of pGL3-meq 
promoter and 500 ng of one of Chimeric Meq expressing vectors (A) or Meq single 
amino acid mutants (B). Twenty four hours after the transfection, cells were collected 
and analyzed for luciferase activity. Values were reported as fold activation relative to 
the luciferase activity of vector vector. The experiment was done three times in 
triplicate. Error bars indicate SEM.  
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2.3.6. All three Meq proteins suppress the MDV pp38/pp14 bidirectional early 
promoter 
MDV early proteins pp38/24 and pp14 are expressed in opposite directions from 
a bi-directional promoter, which is located in the region of MDV origin of replication 
(MDV-Ori). Meq/Meq homodimers have been shown to suppress gene expression from 
this bi-directional promoter (Levy et al., 2003b). We asked whether Md5-Meq, CVI-
Meq and CVI-LMeq proteins have the same suppressive effect on this promoter. 
Transfection of pGL2-pp38 or pGL2-pp14 promoters together with pcDNA vectors 
expressing each of the Meq proteins, was performed in DF-1 cells. Although statistically 
not significant, our results show that all three Meq proteins suppressed transcription 
from both pp38 (Fig. 11A) and pp14 (Fig. 11B) promoters. Since the Meq binding motif 
in this region has been identified as an ACACA motif (Levy et al., 2003b), in order to 
determine whether the suppressive effect of Meq proteins on these promoters is due to 
binding the ACACA motif, we cloned a 3X MDV Ori sequence into the luciferase 
reporter vector pGL2 and repeated the luciferase assay with  pGL2-3XOri vector. Our 
results show that all three Meq proteins suppressed transcription from this construct, 
which was statistically significant when compared to the control vector (Fig. 11C). This 
indicates that all three Meq proteins are capable of binding to ACACA sequence present 
in the bidirectional promoter and this interaction might be the cause of transcriptional 
suppression of this promoter. 
 
 51 
     
Fig. 11. Transrepression by Meq of MDV-1 bi-directional promoter (pp38 and pp14) 
and Meq binding motif (ACACA) in MDV-1 Ori. Two hundred and fifty ng of pGL2-
pp38 promoter (A) pGL2-pp14 promoter (B) or pGL2-3XOri vector (C) were co-
transfected with 125 ng of control vector or vector expressing one of three Meq proteins 
in DF-1 cells. Luciferase activity was measured 24 hr later and fold activation relative to 
control vector indicated in the graph represents mean of three experiments done in 
triplicate. Error bars indicate SEM.  
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2.3.7. Activation of MDV gB late promoter by Meq proteins  
Glycoprotein B (gB) is one of the major MDV glycoproteins and has been shown 
to be essential for viral replication (Schumacher et al., 2000). Using a ChIP assay, a 
previous study has shown Meq binds to the MDV gB promoter (Levy et al., 2003b). In 
order to evaluate the functional significance of this binding, we cloned the gB promoter 
of Md5 into the pGL3 luciferase reporter vector. This promoter contains an AP-1 like 
sequence (AGTCA), where Meq might bind. Plasmids expressing Md5-Meq, CVI-Meq, 
and CVI-LMeq proteins or control pCDNA vector were co-transfected into DF-1 cells 
along with the pGL3-gB promoter reporter vector and the luciferase activity was 
determined in the cell lysates 24 h after transfection. As shown in Fig. 12, there was a 
statistically significant difference between Md5-Meq and CVI-Meq proteins even though 
all three Meq proteins activated MDV gB promoter. Our results show for the first time 
that Meq is capable of transactivating the MDV gB late promoter and thus may play a 
role in viral replication. 
2.3.8. Activation of cellular MMP-3 and Bcl-2 promoters by Meq proteins 
T cell tumors produced by Marek’s disease are metastatic in nature and infiltrate 
various internal organs. Breakdown of stromal extracellular matrix (ECM) by matrix 
metallo-proteinases (MMPs) is critical for tumor invasion and AP-1 factors are known to 
regulate the expression of MMPs (Westermarck and Kahari, 1999). Since, Meq is related 
to AP-1 factors structurally and functionally, we wanted to test Meq transcriptional 
activity on the MMP promoter. To achieve this objective, we used a MMP-3 promoter 
that contains two AP-1 binding sites.  
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Fig. 12. Transactivation of MDV-1 gB promoter by Meq proteins. pGL3-gB promoter 
(250 ng) was transfected together with 125 ng of pcDNA or pcDNA expressing Md5-
Meq, CVI-Meq and CVI-LMeq proteins. DF-1 cells were lysed 24 hr after transfection 
to measure the luciferase activity. Fold activation of the luciferase activity was reported 
in the graph relative to that of control vector. The experiment was done three times in 
triplicate. Error bars indicate SEM.  
 
This promoter construct was co-transfected simultaneously along with one of the 
three pCDNA Meq expressing vectors or control pCDNA vector into DF-1 cells. As 
shown in Fig. 13A, Md5-Meq, CVI-Meq, and CVI-LMeq transactivated the MMP-3 
promoter. However, these effects were not statistically significant. Nevertheless, these 
results indicate the Meq protein of MDV might contribute to dissemination of tumor 
cells to various organs by increasing the transcription of MMP-3. 
Meq has also been shown to possess anti-apoptotic function and this function 
could be attributed to its ability to increase the transcription of anti-apoptotic genes such 
as Bcl-2 (Levy et al., 2005). We asked whether this increase could be due to direct 
transactivation of the Bcl-2 promoter by Meq. Chicken Bcl-2 promoter was amplified  
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Fig. 13. Md5 and CVI-Meq proteins transactivate cellular promoters MMP-3 and Bcl-2. 
DF-1 cells were co-transfected with 250 ng of pGL3-MMP-3 promoter (A) or pGL3-Bcl-
2 promoter (B) along with 500 ng of pcDNA control vector or pcDNA expressing Md5-
Meq or CVI-Meq or CVI-LMeq long. Cells were processed 24 hr post transfection for 
luciferase activity. Activation by each Meq protein was represented as fold activation 
relative to the activation by control vector. The experiment was done three times in 
triplicate. Error bars indicate SEM. 
 
 
from lymphocytes and cloned in a luciferase reporter vector. DF-1 cells were subjected 
to simultaneous transfection of pGL3-Bcl-2 promoter and either pcDNA, pMd5-Meq, 
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pCVI-Meq, or pCVI-LMeq. Meq proteins of both Md5 and CVI988 strains activated the 
chicken Bcl-2 promoter (Fig. 13B) and further, the transactivation difference between 
Md5 and CVI proteins was found to be statistically significant. Therefore, our study 
suggests that the anti-apoptotic function of Meq might be related to its ability to directly 
transactivate the Bcl-2 promoter. 
2.4. Discussion 
MDV vaccines prepared from attenuated GaHV-2, GaHV-3, and MeHV-1 (MDV 
serotypes 1, 2, and 3) are largely used to control MD in chickens (Witter, 1998) . Only 
MDV-1 induces T cell tumors while MDV-2 and MDV-3 do not cause MD in chickens. 
MDV-1 includes oncogenic strains and can be attenuated into non-oncogenic strains by  
serial passage in cell culture (Churchill et al., 1969a; Nazerian, 1970; Rispens et al., 
1972; Vielitz and Landgraf, 1971; Witter, 1982) or recombinant DNA techniques 
(Brown et al., 2006; Cui et al., 2005; Hung et al., 2002; Lee et al., 2008; Tischer et al., 
2002). CVI988/Rispens, a MDV-1 attenuated non-oncogenic vaccine strain, 
currentlyprovides the best protection against MD due to its close genetic relatedness to 
MDV-1 oncogenic strains (Spatz et al., 2007b). The meq gene has been implicated in the 
development of malignant T cell tumors in chickens (Brown et al., 2006; Lupiani et al., 
2004). Currently, it is unclear why attenuated CVI988/Rispens does not cause tumors 
even though it encodes for the oncoprotein Meq. In this study, we attempted to 
characterize the in vitro transformation and transactivation properties of CVI-Meq 
proteins with reference to the Meq protein of Md5, a very virulent MDV oncogenic 
strain. 
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Due to the lack of an in vitro T cell transformation system to study 
transformation by Meq, experiments have been performed with fibroblasts. We 
previously showed that Meq is able to transform rat and chicken fibroblast cell lines 
(Levy et al., 2005; Liu et al., 1998). Our results here confirm that Md5-Meq is an 
oncogene and that it transforms fibroblast cell lines such as Rat-2 and NIH3T3. In 
addition, CVI-Meq proteins are capable of transforming both Rat-2 and NIH3T3 cell 
lines indicating that the amino acid differences observed between Md5 and CVI-Meq 
proteins have no effect on their in vitro transformation properties. Recently, Meq has 
been shown to transform DF-1 cells by up-regulating genes such as JTAP-1, JAC, and 
HB-EGF, which are implicated in the transformation pathway of v-Jun (Levy et al., 
2005). By knocking down the expression of c-Jun, Levy et al (2005) showed that this 
pathway is essential for the growth of Meq expressing cells. It should be noted here that 
there are no differences in the leucine zipper region of Md5-Meq, CVI-Meq, and CVI-
LMeq proteins. Hence, all should interact with c-Jun through the leucine zipper in a 
similar manner and possibly Meq/c-Jun interactions might have lead to the 
transformation of fibroblasts by CVI-Meq proteins. Logically, the next step would be to 
determine the transformation properties of CVI-Meq proteins in vivo. However, our 
attempts to study the transformation properties of CVI-Meq proteins in chickens using 
replication competent avian leukosis viruses were unsuccessful due to the instability of 
the insert and truncation of meq genes in this vector system during virus replication.  In 
previous studies, replication defective virus expressing Meq induced only 5% sarcomas 
in chickens (Liu et al., 1998) and thus far, Meq has been shown to transform only 
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fibroblast cell lines but not primary fibroblasts. These findings imply that Meq is a weak 
oncoprotein.  
Meq is a bZIP protein that structurally and functionally resembles proteins of 
bZIP family such as c-Jun and c-Fos. In one study, DNA binding and transactivation 
domains of Meq were shown to be interchangeable with those of c-Jun resulting in no 
changes to their transactivation and transformation functions (Liu et al., 1999a). 
Additionally, Meq has been shown to function as a transcriptional factor for its own 
promoter. Meq dimerizes with itself or with c-Jun via the leucine zipper present in its 
DNA binding domain. Meq/c-Jun heterodimers have been shown to carry out stronger 
DNA binding activity for AP-1 like sequences present in the meq promoter (Qian et al., 
1995). Data presented herein shows that the meq promoter is activated by Md5-Meq and 
this transcriptional activity is further increased in the presence of over-expressed c-Jun. 
However, CVI-Meq and CVI-LMeq failed to activate the meq promoter. Interestingly, 
CVI-Meq proteins activated the meq promoter in the presence of over expressed c-Jun. 
These results reinforce c-Jun as a major interacting protein of Meq and also suggest that 
the CVI-Meq proteins are weak transactivators and only activate the meq promoter in the 
presence of high levels of c-Jun. In addition, the weak transactivation activity of CVI-
Meq could in turn cause low levels of Meq expression in CVI vaccinated chickens and in 
the absence of sufficient Meq, development of T cell tumors might fail to occur. Studies 
quantifying the expression of Meq in chickens vaccinated with CVI988/Rispens will 
answer whether low-level expression is the cause for non-oncogenicity of CVI.  
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Md5 and CVI-Meq proteins bind to the meq promoter irrespective of whether 
CK-Jun is co-expressed. Thus, amino acid differences found in their DNA binding 
domains had no effect on their transactivation properties. When co-expressed, CVI-Meq 
proteins reduced activation of the meq promoter by Md5-Meq. Findings presented here 
are in agreement with studies by Chang et al (2002b) who also showed that CVI-LMeq 
suppressed activation of the meq promoter by Md5-Meq. In a mixed infection of 
CVI988/Rispens and Md5 or other virulent viruses, CVI-Meq proteins may compete for 
the binding sites in the meq promoter and subsequently suppress expression of Meq. 
Luciferase assays with DNA binding domain chimeric Meq proteins indicated 
that both DNA binding and transactivation domains are required for full activation of the 
meq promoter by Md5-Meq protein. Even though, both DNA binding and transactivation 
domains of Md5-Meq protein increase the transactivation activity of chimeric Meq 
proteins on the meq promoter, this activity is far less compared to Md5-Meq protein. We 
expected differences in transactivation between Md5-Meq and CVI-Meq proteins would 
be due to differences in the transactivation domain because both proteins are capable of 
binding the meq promoter. But both Md5-CVI-Meq and Md5-CVI-LMeq chimeric 
proteins, with transactivation domain from CVI-Meq proteins, showed activation 
comparable to CVI-Md5-Meq chimeric protein, which has the Md5-Meq transactivation 
domain. Our study identifies residues at positions 71 and 320 are important for full 
functionality of Md5-Meq as transcriptional factor for its own promoter. However, 
further studies are required to understand the significance of these residues on Meq 
function.  
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Whether Meq plays a role in virus replication and latency, in addition to its direct 
role in transformation, is unclear.  Meq has been shown to be highly expressed in 
latently infected transformed T lymphocytes (Qian et al., 1995) and is also expressed, as 
an early gene, during lytic infection (Parcells et al., 2001). An Md5 virus in which both 
copies of the meq gene were deleted replicated similar to parental Md5 in vitro (Lupiani 
et al., 2004). Interestingly, replication of the meq mutant MDV was reduced at the time 
of latency and/or reactivation but not during the early cytolytic phase of the infection in 
chickens (Brown et al., 2006, Lupiani et al., 2004).  These studies suggested that Meq 
could play a role in latency and/or reactivation. The MDV-1 pp38/pp14 bi-directional 
promoter includes the MDV-1 origin of replication. It was initially thought that pp38 
protein played a role in T cell transformation (Xie et al., 1996).  However, our recent 
work with a pp38 deletion mutant virus showed that pp38 is non-essential for 
transformation but essential for lytic infection (Reddy et al., 2002). It has been shown 
Meq/Meq homodimers but not Meq/c-Jun heterodimers suppress transcription from this 
bi-directional promoter (Levy et al., 2003b). Our results show that not only Md5-Meq, 
but also CVI-Meq and CVI-LMeq suppress transcription of this bidirectional promoter. 
In addition, all three Meq proteins suppressed transcription of a promoter construct 
containing the ACACA sequence present in the MDV-1-origin of replication; it is 
possible that this transcriptional suppression by Meq may be required to maintain the 
latency. Additionally, Meq activates MDV-1 gB late promoter and thereby might 
promote virus replication. However, a previous work suggested Meq is not essential for 
the expression of gB (Lupiani et al., 2004). Interestingly, multiple spliced variants and 
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microRNAs have been identified in the region of the meq gene. Thus, the role of Meq in 
the biology of MDV-1 is very complex and Meq may promote latency or reactivation 
depending upon its dimerization partner, phosphorylation status, level of expression of 
splice variants, and microRNAs. 
Meq binds AP-1 like sequences present not only on its own promoter but also on 
cellular promoters. For example, studies have shown Meq binds and activates the 
chicken IL-2 promoter (Levy et al., 2003b; Okada et al., 2007). Recently, Meq was 
shown to increase transcription of the anti-apoptotic Bcl-2 gene (Levy et al., 2005). Our 
study suggests that this increase might be due to the activation of chicken Bcl-2 
promoter by Meq. T cell tumors produced by Meq are malignant in nature and are found 
in various organs such as liver, spleen, skin, and nerves. Malignant cells disseminate in 
the host by breaking down extracellular matrix proteins. bZIP proteins such as c-Jun and 
c-Fos bind AP-1 sequences on the MMP-3 promoter and up regulate its transcription 
(Westermarck and Kahari, 1999). Similarly, all three Meq proteins studied herein 
activated the MMP-3 promoter. As with most of the promoters analyzed in this study, 
Md5-Meq activated the MMP-3 promoter better than both CVI-Meq proteins. 
When compared with oncogenic strains, CVI988 encodes truncated ORF49.1, 
ORF5.5/ORF75.91 and vIL-8, lacks ORF6.2/ORF75.6 and has amino acid changes in 
UL36 and UL49 (Spatz et al., 2007a); however, whether these changes have an effect on 
oncogenesis remains to be determined. CVI988 shows high homology with other 
oncogenic strains for genes that play a role in pathogenesis including pp38, lipase, vTR, 
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and viral lipase (Fragnet et al., 2003; Spatz et al., 2007a) while it shows several amino 
acid differences in Meq, suggesting that Meq may play an important role in oncogenesis. 
Collectively, our data indicate that CVI-Meq proteins, like Md5-Meq, transform 
fibroblasts. However, CVI-Meq proteins differ from Md5-Meq in their transactivation of 
the meq promoter. While CVI-Meq proteins required c-Jun for the activation of the meq 
promoter, c-Jun was not essential for Md5-Meq mediated activation. Interestingly, 
chimeric Meq proteins in which the DNA binding domain was swapped among Md5-
Meq and CVI-Meq, proteins activated the meq promoter but to levels significantly lower 
than parental Md5-Meq. In addition, amino acid residues at positions 71 and 320 of 
Md5-Meq were found to be essential for its transactivation on the meq promoter. All 
three Meq proteins (Md5-Meq, CVI-Meq, CVI-Meq-L) activated the gB MDV-1 late 
promoter and cellular promoters (MMP-3 and Bcl-2) whereas they suppressed 
transcription from the pp38 and pp14 MDV-1 early promoters. We conclude that both 
CVI-Meq proteins are generally weak transactivators compared to Md5-Meq and this 
might contribute to its non-oncogenicity in vivo. It is important in the future to develop 
recombinant very virulent MDV-1 expressing CVI-Meq protein(s) and conversely, a 
recombinant CVI988/Rispens virus expressing Meq from a very virulent strain to further 
elucidate the role of Meq in MDV-1 oncogenesis.  Our advancement in understanding 
the mechanisms of MDV-1 induced oncogenesis will certainly lead to the development 
of better MDV-1 vaccines. 
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3. THE DNA BINDING AND TRANSACTIVATION DOMAINS OF  
MAREK’S DISEASE VIRUS MEQ ONCOPROTEIN COOPERATIVELY  
DETERMINE THE TRANSFORMATION PHENOTYPE IN CHICKENS 
3.1. Introduction 
Marek’s disease virus serotype 1 (MDV-1) is an important viral pathogen of 
chickens and is responsible for major economic losses to the world broiler industry. 
MDV-1, also known as Gallid herpesvirus 2 (GaHV-2), belongs to the genus Mardivirus 
of the family Herpesviridae. MDV-1 causes T cell lymphomas in peripheral nerves and 
various organs, paralysis of legs and wings, immunosuppression, depression, blindness, 
dermal lesions, and significant mortality in young chickens (Calnek, 2001). MDV-1 
strains vary greatly in their virulence and are classified into mild (m), virulent (v), very 
virulent (vv), and very virulent plus (vv+) pathotypes depending upon the degree of 
disease they cause in vaccinated chickens (Witter, 1997). Currently, several vaccines 
exist that protect chickens against the development of lymphomas, but they do not 
provide sterilizing immunity; thus field strains are able to replicate in vaccinated 
chickens leading to evolution of strains towards greater virulence (Witter, 1997). 
Insights into the mechanisms of transformation by MDV-1 will provide information that 
could be exploited in the design of better vaccines. In this regard, meq (MDV EcoQ 
fragment), the principal transforming gene of MDV-1, is of particular interest for 
researchers. The MDV-1 genome contains unique long (UL) and unique short regions 
(US) both of which are flanked by inverted repeat regions called terminal repeat long 
(TRL), internal repeat long (IRL), terminal repeat short (TRS), and internal repeat short 
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(IRS). Two copies of meq are located in the EcoQ fragments within the repeat long 
regions (TRL and IRL). This oncogene was first identified based on a observation that the 
EcoQ transcripts were abundantly present in MDV transformed T-cell lines such as RP1, 
RP4, and MSB1 as well as in tumors (Jones et al., 1992).  
Meq is a 339 amino acid long bZIP protein, characterized by a DNA binding 
domain (amino acids 1-120) at its amino terminus and a transactivation domain (amino 
acids 121-339) at its carboxy terminus (Jones et al., 1992; Qian et al., 1995). The 
structure and function of Meq closely resembles c-Jun, which is a member of the 
activator protein 1 (AP-1) transcription factor complex (Jones et al., 1992). Like c-Jun, 
Meq forms homodimers with itself and heterodimers with other bZIP proteins. Meq 
binds to the AP-1 like sequences present in its own promoter and the binding affinity and 
transcription activity from the meq promoter can be increased with the co-expression of 
c-Jun (Qian et al., 1995). Chimeric proteins, bZIP-Meq/TA-c-Jun and bZIP-c-Jun/TA-
Meq, exhibit properties similar to those of Meq and c-Jun, suggesting that the bZIP and 
transactivation domains between them complement in the transformation process (Liu et 
al., 1999a). Meq/c-Jun heterodimers preferentially bind cyclic AMP (CRE)- and 12-O-
tetradecanoylphorbol 13-acetate responsive element (TRE)-like sequences, called MERE 
(Meq reponse element) I (Qian et al., 1996). On the other hand, Meq/Meq homodimers 
preferentially bind a consensus sequence ACACACA, called MERE II (Qian et al., 
1996). Meq/Meq homodimers but not Meq/c-Jun heterodimers suppress transcription of 
pp38/pp14, a bidirectional promoter located in the MDV origin of replication (MDV-
Ori) (Levy et al., 2003b). By CHIP assay, Meq has been shown to bind MDV promoters 
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such as meq, ICP4, gB, and gD, all of which contain MERE I sequence and MDV-Ori, 
which contains MERE II sequence (Levy et al., 2003b).  Furthermore, Meq/Jun 
heterodimers bind AP-1 containing chicken promoters such as IL-2. Additionally, Meq 
has been shown to interact with c-Fos, Jun-B, CREB, ATF-1, ATF-2, and ATF-3 
(Brunovskis et al., 1996). The C-terminal domain of Meq, which contains proline 
repeats, has transactivation properties, and at least one proline repeat is required for full 
transactivation activity (Qian et al., 1995). Furthermore, the last 33 amino acids (307-
339), though not sufficient, are critical for its function (Qian et al., 1995). As in the case 
of WT-1, proline rich repeats in the transactivation domain of Meq also have 
transrepression functions when tested in its isolated form (Qian et al., 1995). Though yet 
to be proven, presence of a potential RNA binding motif in the Meq transactivation 
domain (315-SGQIYIQF-322) suggests that Meq can also bind RNA (Lee et al., 2003; 
Liu and Kung, 2000). Meq has also been shown to interact with the putative 
tetramerization domain of chicken p53 via its basic region (amino acids 54-127) 
(Brunovskis et al., 1996).  In addition, the presence of an RB-binding consensus 
sequence (LXCXE) at the end of the b-ZIP domain suggests Meq could potentially 
interact with RB (Liu and Kung, 2000) although this interaction has not been proven. 
Meq localizes predominantly to the nucleoplasm and the nucleolus during all 
phases of the cell cycle. Two basic signal sequences, BR1 (30-RRKKRK-35) and BR2 
(62-RRRKRNRDAARRRRRKQ-77), present at the N-terminus are required for its 
localization (Liu et al., 1997). While either BR1 or BR2 function as nuclear localization 
signals (NLS), BR2 is Meq sole nucleolar localization signal (NoLS). During S-phase 
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Meq can be found in the cytoplasm and colocalizes with CDK2 in the coiled bodies (Liu 
et al., 1999b). It is noteworthy that this colocalization causes phosphorylation of Meq 
serine at the position 42 by CDK2 leading to its translocation into the cytoplasm. Meq 
can also be phosphorylated by PKA, PKC, and MAPK (Liu et al., 1999b). Further, 
colocalization of Meq with PCNA in the nucleoplasm has been reported suggesting a 
role for Meq in DNA replication (Liu and Kung, 2000). 
There are overwhelming evidences that suggest that Meq plays an important role 
in MDV oncogenesis. Meq is required for maintenance of transformation state since 
induction of RNA antisense to meq in MSB-1 cells, a MDV transformed T cell line, 
results in reduced colony formation in soft agar assay (Xie et al., 1996). Meq also 
cooperates with Myb in the maintenance of the transformation phenotype of T9 (an 
MDV transformed cell line) (Le Rouzic et al., 2002). When overexpressed, Meq 
transforms rat fibroblasts (Rat-2), mouse fibroblasts (NIH3T3) and immortalized 
chicken fibroblasts (DF-1 cells) (Ajithdoss et al., 2009; Levy et al., 2005; Liu et al., 
1998). Thus far, Meq has not been shown to transform primary fibroblasts, and it causes 
sarcomas only in 5% of chickens when infected with replication defective retrovirus 
virus carrying the meq gene (Liu et al., 1998). Like Jun and Fos, Meq promotes growth 
of cells in the absence of serum and protects them against apoptosis inducing agents 
including TNF-α, C2-Ceramide, UV irradiation and serum starvation (Liu et al., 1998). 
The anti-apoptotic function of Meq might be due to its ability to increase bcl-2 
expression by directly binding to the promoter and to decrease bax expression (Ajithdoss 
et al., 2009; Liu et al., 1998).  
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 rMd5ΔMeq, a virus in which the meq genes were deleted, failed to induce 
tumors, where as rMd5 virus with intact meq genes caused tumors in susceptible 
chickens (Lupiani et al., 2004). This study provided compelling evidence that Meq is 
essential for transformation of T lymphocytes. Additional evidence that Meq is involved 
in transformation came from the studies of a virus with mutation in the Meq that 
eliminated the interaction with C-terminal-binding protein (CtBP) domain and was 
found to be nononcogenic in chickens (Brown et al., 2006). It has been suggested that 
Meq transforms via the v-Jun pathway. Observations that support this hypothesis are: (1) 
morphology of Meq transformed DF-1 cells are similar to v-Jun transformed cells, (2) 
Meq protects DF-1 cells against apoptosis, (3) up-regulation of genes such as JTAP-1, 
JAC, and HB-EGF, which are implicated in v-Jun transformation process, and (4) Meq 
cooperates with c-Jun in the transformation of DF-1 cells (Levy et al., 2005). 
Furthermore, a recent work in our laboratory has suggested that Meq/Meq homodimers 
are insufficient for inducing lymphomas in chickens (Suchodolski et al., 2009).  
Analysis of meq genes has demonstrated that mutations in Meq correlate with the 
virulence of MDV strains (Shamblin et al., 2004). For example, low virulence strains 
have two point mutations (positions 71 and 77) in the N terminus and an insertion in the 
C terminus. On the other hand, high virulence MDV strains contain point mutations in 
the proline-rich repeats and the transactivation domain. We have recently shown that 
Meq proteins from the non-oncogenic, attenuated MDV-1 vaccine strain 
CVI988/Rispens are in general weak transactivators although they retain the ability to 
transform fibroblasts (Ajithdoss et al., 2009). Remarkably, CVI-Meq proteins in the 
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context of other Md5 genes caused tumors only in 6% chickens when compared to 
parental rMd5 virus, which induced lymphomas in 100% of chickens (Reddy and 
Lupiani, unpublished observations). It is currently unknown whether the DNA binding 
domain or the transactivation domain of Meq is critical for transformation. To address 
this, we constructed two recombinant rMd5 viruses with chimeric Meq proteins, rMd5-
Md5/CVI-Meq and rMd5-CVI/Md5-Meq, by swapping the DNA binding and 
transactivation domains between Md5-Meq and CVI-Meq, and evaluated their 
pathogenicity in chickens. rMd5-Md5/CVI-Meq caused 100% mortality and tumors 
were found in the peripheral nerves and various organs such as the heart, spleen, kidney, 
and gonads. The tumors were bigger in size when compared to tumors induced by rMd5. 
On the other hand, rMd5-CVI/Md5-Meq caused disease in 36% of chickens and lesions 
were primarily in the nerves. rMd5-Md5/CVI-Meq caused primarily type A nerve 
lesions where as rMd5-CVI/Md5-Meq induced predominantly type C lesions in the 
nerves. Based on these findings, we propose that both the DNA binding domain and 
transactivation domain of Meq determines the incidence, tissue distribution and size of 
the lymphomas in chickens. 
3.2. Materials and methods 
3.2.1. Cell culture 
Primary chicken embryonic fibroblasts (CEFs) prepared from specific pathogen 
free (SPF) chicken eggs were used for transfections to recover recombinant viruses. 
Primary duck embryonic fibroblasts (DEFs) were used for preparing virus stock, 
titration, growth kinetics, and reactivation assay. Both CEFs and DEFs were cultured in 
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Leibowitz-McCoy (LM) medium, supplemented with 5% newborn calf serum and 
penicillin-streptomycin, at 37°C. 
3.2.2. Cosmids 
MDV cosmid clones SN5, P89, SN16, A6, and B40 from the very virulent strain, 
Md5, encompassing the entire MDV genome, were used to recover recombinant Md5 
viruses (Reddy et al., 2002) (Figs. 14A & 14B). The EcoQ fragment located in cosmid 
clones A6 and SN5 contains the meq gene (Fig. 14C) and was replaced with Md5/CVI 
EcoQ, or CVI/Md5 EcoQ using a previously described strategy (Cui et al., 2004; 
Suchodolski et al., 2009). The DNA binding domain of Meq is coded by the first 360 
nucleotides while the transactivation domain is coded by the remaining 657 nucleotides 
of the meq gene. In order to construct Md5/CVI EcoQ, or CVI/Md5 EcoQ fragments, at 
first, the Md5 EcoQ fragment was released from cosmids A6 and SN5 using the recA 
assisted restriction endonuclease (RARE) method. Using recA and primers SR1116 (5'-
GAA TCG GAT TTG GAA TAA CCG AAT TCG GTG ATA TAA AGA C-3') and 
SR1117 (5'-GAC ATT ACA AGA ATA GTT TGA ATT CTC GGG ATA ATC TCC C-
3'), EcoRI sites flanking the EcoQ fragment were protected during the EcoRI 
methylation reaction. The unmethylated EcoRI sites were then digested with EcoRI and 
the released EcoQ fragment was subsequently cloned into pCR2.1 vector (Invitrogen, 
Carlsbad, CA) generating pCR2.1 Md5-EcoQ. The EcoRI digested A6 and SN5 cosmids 
were religated generating A6ΔEcoQ and SN5ΔEcoQ.  
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Fig. 14. Construction of chimeric recombinant viruses (A) Organization of the MDV 
genome. It contains unique long (UL) and unique short (US) regions flanked by repeat 
regions (TRL, IRL, IRS, and TRS). (B) Md5 cosmids. Five overlapping cosmids that 
cover entire MDV genome is used for construction and recovery of chimeric viruses. (C) 
Location of EcoQ fragments. Cosmids SN5 and A6 contain the EcoQ fragment. The meq 
gene is located in the EcoQ fragment (D) Location of KpnI sites in vectors. The KpnI 
fragments between pCR2.1 Md5-EcoQ and pCR2.1 CVI-EcoQ vectors were exchanged 
to generate pCR2.1 Md5/CVI-EcoQ and pCR2.1 CVI/Md5-EcoQ vectors. (E). 
Construction of chimeric cosmids. The parental Md5-EcoQ fragments in SN5 and A6 
cosmids were replaced with Md5/CVI-EcoQ or CVI/Md5-EcoQ fragment.  
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Fig. 14. Continued 
 
The EcoQ fragment from attenuated vaccine strain Rispens/CVI988 was obtained 
by EcoRI digestion of Rispens/CVI988 purified DNA, gel purified and cloned into 
pCR2.1 vector (Invitrogen, Carlsbad, CA) generating pCR2.1 CVI-EcoQ. As indicated 
in the Fig. 1D, two KpnI restriction sites, one in the pCR2.1 vector and another in the 
EcoQ fragment, are present in pCR2.1 Md5-EcoQ and pCR2.1CVI-EcoQ vectors. These 
two vectors were digested with KpnI enzyme and the were swapped between them to 
construct pCR2.1 Md5/CVI-EcoQ and pCR2.1 CVI/Md5-EcoQ containing chimeric 
EcoQ fragments.  The integrity of the chimeric EcoQ designated as A6-Md5/CVI-Meq, 
SN5-Md5/CVI-Meq, A6-CVI/Md5-Meq, and SN5-CVI/Md5-Meq, was confirmed by 
EcoRI digestion. 
3.2.3. Recovery of recombinant viruses 
The recovery of rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq viruses was 
done as described (Reddy et al., 2002). Briefly, cosmids SN15, P89, B40, SN5-
 71 
Md5/CVI-Meq, A6-Md5/CVI-Meq, SN5-CVI/Md5-Meq, and A6-CVI/Md5 Meq were 
digested with NotI, phenol-chloroform extracted and ethanol precipitated. To recover 
rMd5-Md5/CVI-Meq, 500 ng of digested and purified cosmids SN15, P89, B40, SN5-
Md5/CVI-Meq, and A6-Md5/CVI-Meq were co-transfected, by the calcium phosphate 
method (Moriuchi et al., 1992), into 1.2 x106 CEF seeded onto 60-mm-diameter dishes.  
Four days post-transfection, cells were be trypsinized, seeded onto a 100-mm dish and 
after the appearance of viral plaques, viral stocks were made in DEF. rMd5-CVI/Md5-
Meq virus was recovered in a similar fashion by co-transfecting CEF with 500 ng of 
digested and purified cosmids SN15, P89, B40, SN5-CVI/Md5-Meq, and A6-CVI/Md5-
Meq. Additionally, two independent transfections for both chimeric viruses were carried 
out and these were termed rMd5-Md5/CVI-Meq #1, rMd5-Md5/CVI-Meq #2, rMd5-
CVI/Md5-Meq #1, and rMd5-CVI/Md5-Meq #2. Previously described rMd5, rMd5-
CVI-Meq and rMd5-CVI-LMeq viruses were used as controls throughout this study 
(Reddy and Lupiani, unpublished observations) (Reddy et al., 2002). 
3.2.4. In vitro growth kinetics assay 
DEFs grown to confluency in 35-mm-diameter dishes were infected with 100 
plaque forming units (PFU) of all five recombinant viruses (rMd5, rMd5-CVI-Meq, 
rMd5-CVI-LMeq, rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq). After 2, 3, 4, and 5 
days of infection, cells were trypsinized, 10- fold diluted and seeded onto fresh DEF 
monolayers in 35-mm-diameter dishes. Plaques were counted 7 days post infection. Two 
experiments were done in duplicate. 
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3.2.5. Southern blot 
 DNA from rMd5, rMd5-CVI-Meq, rMd5-CVI-LMeq, rMd5-Md5/CVI-Meq and 
rMd5-CVI/Md5-Meq viruses infected DEFs was isolated, digested with EcoRI, 
separated on a 1% agarose Tris-borate/EDTA gel, and transferred to a nylon membrane.  
DNA probes, one from total genomic viral DNA (cosmid DNA) and one from the 2.4-kb 
EcoQ fragment were labeled with [32P]dCTP by the random priming method 
(DECAprime II kit, Ambion, Austin, TX) and used to hybridized two independent 
membranes according to standard protocols (Sambrook, 2001). Briefly, membranes 
containing denatured DNA were incubated in prehybridization buffer at 43°C for 1 hr. 
Incubation of membranes with radiolabeled probes was carried out at 43°C overnight. 
Following hybridization, the membranes were washed three times (1-2 hrs each at 43°C) 
with wash buffer (0.2 X SSC plus 0.1% SDS) and autoradiographed. 
3.2.6. Immunofluorescence (IFA) 
Cells infected with recombinant viruses were washed with PBS and fixed with 
ice cold ethanol:acetone solution (6:4) at room temperature for 10 minutes. Following 
the removal of fixing solution, the cells were air-dried, rehydrated with PBS and 
incubated with anti-Meq rabbit serum (Lee et al., 2003) (1:200) or anti-pp38 mouse 
monoclonal (Cui et al., 1990) (1: 200) for 1 hour at 37°C. Following three washes with 
PBS, cells were incubated with goat anti-rabbit FITC labeled secondary antibodies for 
anti-Meq stained cells or with goat anti-mouse FITC labeled secondary antibodies for 
anti-pp38 stained cells for 1 hour at 37°C. Cells were washed 3 times with PBS and 
examined under a fluorescence microscope. 
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3.2.7. Immunohistochemistry (IHC) 
Tissues collected from lymphoid organs (thymus, spleen, and bursa of Fabricius) 
and feather follicles were embedded in optimal cutting temperature compound (Tissue-
Tek OCT; Sakura Finetek, Torrance, CA). Tissue blocks were immediately frozen in 
liquid nitrogen, and kept at –80°C until processed for staining. Eight µm thick sections 
were prepared from the frozen tissue blocks, fixed with cold acetone at –20°C for 5 min, 
and air-dried.  Immunostaining was carried out using the Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA) as directed by the manufacturer. The H19 pp38 
monoclonal antibody (1:3,000) was used as detection antibody. 
3.2.8. Revertant virus 
To recover a revertant virus containing the parental Md5 meq gene, DNA was 
purified from rMd5-CVI/Md5-Meq and rMd5-Md5/CVI-Meq infected CEF and each 
was co-transfected with parental Md5 EcoQ fragment in CEF by the calcium phosphate 
method. Seven days post transfection, transfected cells were overlaid with 0.9% Bacto 
agar, and individual plaques were harvested by trypsinization. Cells from single plaques 
were divided into two aliquots: one was used to infect fresh DEF, and the other was used 
for DNA extraction and PCR analysis. Revertant viruses were identified by using Md5 
meq mismatch primers (BL1455: 5’- AAA AGG AAT CGT GAC GAC G-3’ and 
BL1456: 5’- AGT ATC CGA GGG AAA CTT AG-3’), which amplified only parental 
Md5 meq and not Md5/CVI meq or CVI/Md5 meq at an annealing temperature of 60° C.  
Revertant viruses, rMd5-Md5/CVI-Meq-R and rMd5-CVI/Md5-Meq-R, were then 
expanded and titrated in DEFs. 
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3.2.9. Chicken experiments 
 (a) Experiment 1.  Specific-pathogen-free chickens (Charles River SPAFAS, North 
Franklin, CT) were randomly sorted into seven experimental groups, wing banded and 
raised in modified Horsfall-Bauer isolators. Five groups of day-old chickens (15 per 
group) were inoculated subcutaneously with 5,000 PFU of rMd5, rMd5-CVI-Meq, 
rMd5-CVI-LMeq, rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq viruses. A group of 
10 chickens were inoculated with 5,000 PFU of Rispens/CVI988 vaccine and as a 
negative control, a group of 8 chickens were kept uninoculated. Chickens were 
monitored for the development of MD for a period of 8 weeks. Chickens that died during 
the study or that were euthanized at the termination of the experiment were necropsied 
and nerves were collected for histological evaluation of MD. To examine early viral 
cytolitic infection, two birds from each group were randomly selected and euthanized at 
6 dpi and samples from spleen, thymus, and bursa were collected for 
immunohistochemistry. To examine the reactivation ability of chimeric viruses, three 
chickens from each group were randomly selected and bled at 35 dpi. Following 
centrifugation of heparinized blood at 500 xg for 5 minutes, buffy coats were collected 
and diluted to 106 cells/ml. For each sample, 35-mm plates of freshly seeded DEF 
monolayers were inoculated in duplicates with 106 lymphocytes and viral plaques were 
counted 7 days later. To investigate the ability of chimeric viruses to transmit among 
chickens, three uninoculated chickens were included in each group at the time of 
inoculation. Buffy coats were obtained from contact birds at seven weeks and the 
presence of virus in lymphocytes was determined by PCR using Meq specific primers 
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(SR1118: 5'-GAT CCC GGG GAG ATG TCT CAG GAG CCA GAG C-3' and SR1135: 
5'-GAT CCC GGG TCA GGG TCT CCC GTC ACC TGG AAA CC-3'). In addition, 
DEFs were co-cultured with 1 x106 lymphocytes and examined by IFA for pp38 at 7 dpi. 
 (b) Experiment 2. Nine groups of day-old chickens (15 per group) were inoculated 
subcutaneously with 5,000 PFU of rMd5, rMd5-Md5/CVI-Meq, rMd5-Md5/CVI-Meq 
#1, rMd5-Md5/CVI-Meq #2, rMd5-CVI/Md5-Meq, rMd5-CVI/Md5-Meq #1, rMd5-
CVI/Md5-Meq #2, rMd5-Md5/CVI-Meq-R and rMd5-CVI/Md5-Meq-R viruses. A 
group of 10 chickens were kept uninoculated to serve as negative control. Chickens were 
monitored for MD for a period of 8 weeks. 
3.3. Results 
3.3.1. Construction of chimeric Meq viruses: rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-
Meq  
Previous work in our lab has demonstrated a direct role for Meq in MDV 
oncogenesis as a Meq null virus (rMd5ΔMeq) failed to cause tumors in chickens 
(Lupiani et al., 2004). Intriguingly, attenuated vaccine strain CVI988/Rispens, although 
it codes for Meq, does not induce tumors. CVI-Meq proteins (CVI-Meq and CVI-LMeq) 
contain two and four amino acid substitutions in the DNA binding domain and 
transactivation domains, respectively relative to Md5-Meq. In addition, CVI-LMeq 
contains a 59 amino acid insertion in the transactivation domain. Like Md5-Meq, CVI-
Meq proteins also transform fibroblasts in vitro, but are generally weak transactivators 
when compared to Md5-Meq (Ajithdoss et al., 2009).  Furthermore, rMd5-CVI-Meq and 
rMd5-CVI-LMeq viruses, in which Md5-meq was replaced by CVI-meq or CVI-L-meq 
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caused tumors in 6% and 20% of chickens, respectively while parental rMd5 with Md5-
meq gene induced tumors in 100% of chickens (Reddy and Lupiani, unpublished data). 
This study demonstrated that CVI-Meq proteins are very weakly oncogenic in the 
background of other Md5 genes and thus can be used to define the role of the DNA 
binding domain (DBD) and transactivation domain (TAD) of Md5-Meq in oncogenesis. 
To this end, we generated two chimeric rMd5 viruses: rMd5-Md5/CVI-Meq (DBD of 
Md5 and TAD of CVI) and rMd5-CVI/Md5-Meq (DBD of CVI and TAD of Md5) by 
exchanging domains between Md5- and CVI-Meq proteins. The amino acid differences 
in the DBD and TAD among Md5-Meq, CVI-Meq, Md5/CVI Meq and CVI/Md5 Meq 
proteins, are noted in Fig. 15. To obtain chimeric Meq rMd5 viruses, KpnI digested 
DNA fragments of pCR2.1 Md5-EcoQ and pCR2.1 CVI-EcoQ vectors were exchanged 
to create pCR2.1 Md5/CVI-EcoQ and pCR2.1 CVI/Md5-EcoQ vectors (Fig. 14C). 
Subsequently, these chimeric EcoQ fragments were cloned in both A6ΔEcoQ and 
SN5ΔEcoQ cosmids (Fig. 14D). rMd5-Md5/CVI-Meq virus was recovered by co-
transfection of A6-Md5/CVI-Meq, SN5-Md5/CVI-Meq, SN16, B40, and P89 cosmids 
while rMd5-CVI/Md5-Meq virus was generated by transfecting A6-CVI/Md5 Meq, 
SN5-CVI/Md5 Meq, SN16, B40, and P89 cosmids in CEF. To confirm that no 
unforeseen gene rearrangements occurred during the generation of viruses by 
homologous recombination of the five cosmids, the integrity of the viral genomes was 
confirmed by Southern blot analysis. As shown in Fig. 16, rMd5, rMd5-CVI-Meq, 
rMd5-Md5/CVI-Meq and rMd5-CVI/Md5 Meq viruses showed identical EcoRI 
digestion patterns. As anticipated, except for a large size EcoQ fragment due to  
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Fig. 15. Schematic representation of Meq proteins. When compared to Md5-Meq, CVI-
Meq contains 2 amino acid differences in the DNA binding domain and 4 amino acids 
differences in the transactivation domain. Chimeric Meq proteins are constructed by 
exchanging the DNA binding and transactivation domains between Md5-Meq and CVI-
Meq. 
 
 
 
 
 
Fig. 16. Southern blot analysis of viral genomes. DNA isolated from DEF infected with 
recombinant viruses was digested with EcoRI and transferred to nylon membranes. The 
membranes were probed with either radiolabelled viral genome (A) or radiolabelled 
EcoQ fragment DNA (B). Lanes: (1) rMd5, (2) rMd5-CVI-Meq, (3) rMd5-CVI-LMeq, 
(4) rMd5-Md5/CVI-Meq, and (5) rMd5-CVI/Md5-Meq.  
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Fig. 17. Expression of Meq. DEF infected with all five recombinant viruses were fixed 
with ice cold ethanol:acetone solution and tested with polyclonal anti-Meq serum. 
Except for negative control, Meq expression in nucleus is observed with all five viruses. 
 
 
the 180 bp insertion in the meq gene, rMd5-CVI-LMeq showed no differences in the 
genome arrangement. Expression of Meq by these viruses was examined in DEFs 
infected with all five recombinant viruses using rabbit anti-Meq polyclonal antibodies, 
and was predominantly found in the nucleus (Fig. 17). This shows that chimeric Meq 
proteins are expressed from rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq viruses and 
there is no change in their cellular localization properties. 
3.3.2. In vitro and in vivo growth properties of rMd5-Md5/CVI Meq and rMd5-CVI/Md5 
Meq 
Meq has been shown to play no role in the replication of MDV in vitro (Lupiani 
et al., 2004); however, it affects viral replication at or after 2 weeks post infection in 
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chickens (Brown et al., 2006; Lupiani et al., 2004).  To investigate whether chimeric 
Meq proteins, Md5/CVI-Meq and CVI/Md5-Meq, have any effect on the viral 
replication, DEFs grown to confluency in 35 mm dishes were infected with 100 PFU of 
rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq. As controls, rMd5, rMd5-CVI-Meq, 
and rMd5-CVI-LMeq viruses were also included. As expected, the in vitro growth 
properties of rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq were comparable to those 
of rMd5, rMd5-CVI-Meq, and rMd5-CVI-LMeq at all the time points studied (days 2, 3, 
4, and 5) (Fig. 18) suggesting that, like parental Md5- and CVI-Meq proteins, the 
chimeric proteins, have no effect on viral replication in vitro.  
 
 
 
 
Fig. 18. In vitro growth assay.  DEFs were infected with 100 PFU of the indicated 
viruses. Cells were harvested at days 2, 3, 4, and 5 post infection and virus titers were 
determined on fresh DEF. The experiment was done twice in duplicates.  
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To investigate the role of chimeric Meq proteins (Md5/CVI-Meq and CVI/Md5-
Meq) in virus replication, at 6 dpi, two chickens from each group were euthanized and 
lymphoid organs (spleen, thymus, and bursa of Fabricius) were collected, routinely 
processed for immunohistochemistry and stained with pp38, an MDV early protein, 
monoclonal antibody. As shown in Fig. 19 all five recombinant viruses replicated to 
similar levels, as no difference in pp38 antigen expression was observed in all three 
organs examined, suggesting that early cytolytic infection in chickens was not affected 
by chimeric Meq proteins.  
3.3.3. Reactivation properties of rMd5-Md5/CVI Meq and rMd5-CVI/Md5 Meq 
In order to determine if chimeric Meq proteins affects the ability of viruses to 
reactivate from peripheral blood lymphocytes, buffy coats were isolated from three 
chickens in each experimental group at 35 dpi. For reactivation, 1x106 lymphocytes were 
added to confluent monolayers of DEFs seeded in 35 mm culture dishes and plaques 
were counted 7 days later. As shown in Table 1, maximum number of plaques was 
obtained for rMd5, followed by rMd5- Md5/CVI-Meq; intermediate number of plaques 
was obtained with rMd5-CVI/Md5-Meq and, as expected, the number of plaques from 
the rMd5-CVI- Meq, and rMd5-CVI-LMeq was significantly lower.  
3.3.4. Transformation properties of rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-Meq 
To examine the ability of chimeric Meq proteins to induce tumors, inoculated 
chickens were observed for up to 8 weeks, and those that developed MD during the 
experiment or those that remained at termination were euthanized and necropsied (Table 
2). 
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Fig. 19. In vivo replication of viruses in the lymphoid organs. Specific pathogen free 
chickens were infected with 5000 PFU of indicated viruses. The spleen (A), bursa (B), 
and thymus (C) were collected randomly from two chickens per group and routinely 
processed for immunohistochemistry. For staining, anti-pp38 antibody was used as 
primary antibody. 
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Table 1. Reactivation assay. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Incidence of Marek’s disease. 
Experiment 1 Experiment 2 
Group No of chickens with MD/Total 
chickens (%) 
Mean 
death 
time 
(days) 
No of chickens 
with MD/Total 
chickens (%) 
Mean 
death 
time 
(days) 
Control 0/10 (0) NA 0/10 (0) NA 
Rispens 0/8 (0) NA ND NA 
rMd5 15/15 (100) 38.7 13/13 (100) 35.6 
rMd5-CVI Meq 1/15 (6) 55.0 ND NA 
rMd5-CVI-LMeq 3/15 (20) 52.3 ND NA 
rMd5-Md5/CVI-Meq 15/15 (100) 34.6 15/15 (100) 31.5 
rMd5-CVI/Md5-Meq 7/15 (46) 45.0 3/13 (23) 35.6 
rMd5-Md5/CVI-Meq #1 ND NA 12/12 (100) 35.0 
rMd5-Md5/CVI-Meq #2 ND NA 15/15 (100) 32.1 
rMd5-CVI/Md5-Meq #1 ND NA 4/12 (33) 49.3 
rMd5-CVI/Md5-Meq #2 ND NA 6/14 (42) 38.1 
rMd5-Md5/CVI-Meq-R ND NA 13/13 (100) 34.1 
rMd5-CVI/Md5-Meq-R ND NA 14/15 (93) 39.6 
  
Note: ND- not done; NA- not applicable 
 
Virus No of plaques per one million lymphocytes ± SD 
Control 0 
Rispens 11 ± 4 
rMd5 117 ± 21 
rMd5-CVI Meq 6 ± 5 
rMd5-CVI-LMeq 27 ± 9 
rMd5-Md5/CVI 
Meq 99 ± 27 
rMd5-CVI/Md5 
Meq 11± 4 
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Chickens from the uninoculated and CVI988/Rispens inoculated control groups 
did not die or develop MD during the duration of the experiment (Fig. 20). As expected, 
chickens inoculated with rMd5-CVI-Meq and rMd5-CVI-LMeq showed 7 and 20% MD, 
respectively (Fig. 20). In stark contrast, 100% of the chickens inoculated with rMd5-
Md5/CVI-Meq and rMd5, had MD before the completion of the experiment (Fig. 20).  
On the other hand, 46% of chickens that were inoculated with rMd5-CVI/Md5-Meq had 
MD (Fig. 20). To confirm that the differences observed in the phenotype were due to the 
chimeric Meq proteins and not to unwanted mutations in other regions of the MDV 
genome, two additional clones (#1 and #2) of each of the chimeric viruses were 
generated in two additional independent transfections and the viruses were tested for 
pathogenesis in chickens as indicated above (Figs. 21-22). 
 
 
Fig. 20. Survival curve (experiment 1). SPF chickens were infected with 5000 PFU of indicated 
viruses and were maintained in isolation units for a period of 8 weeks. The mortality pattern for 
each virus was noted and survival percentage for each virus is indicated in the X-axis. 
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Fig. 21. Survival curve for rMd5-Md5/CVI-Meq (experiment 2). Specific pathogen free chickens 
were infected with 5000 PFU of rMd5-Md5/CVI-Meq, rMd5-Md5/CVI-Meq #1, and rMd5-
Md5/CVI-Meq #2 viruses. Infected chickens were maintained in isolation units for a period of 8 
weeks. The mortality pattern for each virus was noted and survival percentage for each virus is 
indicated in the X-axis.  
 
Fig. 22. Survival curve for rMd5-CVI/Md5-Meq (experiment 2). Specific pathogen free chickens 
were infected with 5000 PFU of rMd5-CVI/Md5-Meq, rMd5-CVI/Md5-Meq #1, and rMd5-
CVI/Md5-Meq #2 viruses. Infected chickens were maintained in isolation units for a period of 8 
weeks. The mortality pattern for each virus was noted and survival percentage for each virus is 
indicated in the X-axis. 
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Inoculation of chickens with rMd5-Md5/CVI-Meq #1 and rMd5-Md5/CVI-Meq 
#2 resulted in 100% MD mortality (Fig. 21) while the MD percentage for chickens that 
were inoculated with rMd5-CVI/Md5-Meq #1 and rMd5-CVI/Md5-Meq #2 were 33 and 
42%, respectively, which is comparable to that of rMd5-CVI/Md5-Meq group (23% 
MD) (Fig. 22).  
The transformation phenotype of rMd5-Md5/CVI-Meq was quite different from 
rMd5 and rMd5-CVI/Md5-Meq (Table 3). In addition to lesions in the peripheral nerves 
(Figs. 23 & 24), rMd5-Md5/CVI-Meq induced tumors at high levels of tumors in the 
heart (25-60%), spleen (20-50%), kidney (35-60%), and gonads (6-25%) and the tumors 
were of an unusual large size (Figs. 25-27). Interestingly, in experiment 1, one of the 
chickens infected with rMd5-Md5/CVI-Meq had tumors in the liver, intestines, pancreas, 
and proventriculus besides the kidney, spleen, and heart. On the other hand, rMd5 
caused visceral tumors at a low frequency in heart (15-33%), spleen (6-23%), kidney (0-
6%) and gonads (0-6%) while rMd5-CVI/Md5-Meq rarely induced tumors in the heart 
(0-8%) and spleen (0-7%). Further, rMd5-CVI/Md5-Meq caused no tumors in the liver, 
gonads, and kidney.  
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  Table 3. Frequency of gross visceral tumors. 
  
 
 
Virus 
 
Heart (%) 
 
Spleen (%) 
 
Liver (%) 
 
Gonads (%) 
 
Kidney (%) 
 
Control (Expt #1) 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 0/8 (0) 
Control (Expt #2) 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0) 
Rispens (Expt #1) 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0) 0/10 (0) 
rMd5-CVI-Meq 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 
rMd5-CVI-LMeq 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 
rMd5 (Expt #1) 5/15 (33) 1/15 (6) 1/15 (6) 1/15 (6) 1/15 (6) 
rMd5 (Expt #2) 2/13 (15) 3/13 (23) 0/13 (0) 0/13 (0) 0/13 (0) 
rMd5-Md5/CVI-Meq (Expt #1) 5/15 (33) 7/15 (46) 4/15 (26) 1/15 (6) 9/15 (60) 
rMd5-Md5/CVI-Meq (Expt #2) 7/14 (50) 6/14 (42) 1/14 (7) 3/14 (21) 5/14 (35) 
rMd5-Md5/CVI-Meq #1 (Expt #2) 3/12 (25) 6/12 (50) 0/12 (0) 3/12 (25) 6/12 (50) 
rMd5-Md5/CVI-Meq #2 (Expt #2) 9/15 (60) 3/15 (20) 0/15 (0) 2/15 (13) 6/15 (40) 
rMd5-CVI/Md5-Meq (Expt #1) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 0/15 (0) 
rMd5-CVI/Md5-Meq (Expt #2) 0/13 (0) 0/13 (0) 0/13 (0) 0/13 (0) 0/13 (0) 
rMd5-CVI/Md5-Meq #1 (Expt #2) 1/12 (8) 0/12 (0) 0/12 (0) 0/12 (0) 0/12 (0) 
rMd5-CVI/Md5-Meq #2 (Expt #2) 0/14 (0) 1/14 (7) 0/14 (0) 0/14 (0) 0/14 (0) 
rMd5-Md5/CVI-Meq-R (Expt #2) 3/13 (23) 10/13 (76) 0/13 (0) 7/13 (53) 8/13 (61) 
rMd5-CVI/Md5-Meq-R (Expt #2) 3/15 (20) 3/15 (20) 0/15 (0) 0/15 (0) 0/15 (0) 
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Fig. 23. Classical MD symptoms in chickens. Chickens infected with rMd5-Md5/CVI-
Meq showed unilateral (A) or bilateral leg paralysis (B) or wing paralysis (C) or 
torticollosis (D). Similar neurological signs were also observed in rMd5 (E) and in 
rMd5-CVI/Md5-Meq (F) infected chickens. 
 
A B 
C D 
E F 
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Fig. 24. Histology of nerve lesions. Nerves from control birds show neither lymphocyte 
nor lymphoid infiltration (negative). Type C lesion is characterized by minimal 
infiltration of small lymphocytes. Type B lesion has moderate infiltration of lymphoid 
cells along with edema. Type A lesion is severe and is characterized by massive 
infiltration of lymphoid cells. Type A lesions were observed in rMd5 and rMd5-
Md5/CVI-Meq infected chickens. Few birds infected with rMd5-CVI/Md5-Meq had 
type A lesions and the rest had type C lesions. Lesions in rMd5-CVI-Meq or rMd5-CVI-
LMeq infected birds were of type C. 
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Fig. 25.  Kidney tumors in rMd5-Md5/CVI-Meq infected chickens (A-E). Tumors are 
bigger in size and generally involve all the lobes. Tumors of infected chicken are 
compared with a control bird on the left in E. 
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Fig. 26. Visceral tumors in rMd5-Md5/CVI-Meq infected chickens. A. Tumors in the 
testicles. B. Tumors in the ovary. C. Multiple tumors in the heart. D. Tumors in the 
proventriculus, entire intestines, pancrease, and spleen. E. Tumors in the liver in multiple 
areas. F. Tumors in the intestine. G. Tumors in the spleen. Compare the size with the 
uninfected spleen. 
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Fig. 27. Histological examination of visceral tumors. Massive infiltration of lymphoid 
cells in the ovary, kidney, spleen, proventriculus, and intestines were observed in 
chickens infected with rMd5-Md5/CVI-Meq. 
 
These data collectively suggest: (1) Md5/CVI-Meq is more oncogenic than 
CVI/Md5-Meq; (2) Md5/CVI-Meq is more or at least as oncogenic as Md5-Meq (3) 
Md5/CVI-Meq retains the pathogenicity of Md5-Meq albeit containing the TAD of 
CVI988, thus indicating that DBD plays an important role in transformation; (4) When 
compared to CVI-Meq, CVI/Md5-Meq, which contains the TAD of Md5, is more 
virulent, thus suggesting that the TAD also plays a role in transformation; and (5) 
combination of DBD and TAD determines the transformation potential of Meq. 
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3.3.5. Transmission ability of rMd5-Md5/CVI Meq and rMd5-CVI/Md5 Meq   
Fully productive replication of MDV occurs only in feather follicular epithelial 
cells (FFE), where cell free virus is produced and released serving as a source of 
infection for other susceptible chickens. We therefore investigated whether rMd5-
Md5/CVI-Meq, and rMd5-CVI/Md5-Meq viruses replicate in FFE, an indication of 
transmissibility. To address this, skin from two randomly selected chickens from groups 
of chickens that were infected with rMd5, rMd5-CVI-Meq, rMd5-CVI-LMeq, rMd5-
Md5/CVI-Meq or rMd5-CVI/Md5-Meq were collected at 8 weeks post inoculation, 
processed, and stained with anti-pp38 antibody. As shown in Fig. 28, positive pp38 
staining was observed in all five recombinant viruses.  
 
 
Fig. 28. Viral replication in feather follicular epithelium (FFE). Feather follicles were 
collected from few chickens in each group at the end of the experiment and stained with 
H19 pp38 monoclonal antibody. 
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In addition, inoculation of DEFs with buffy coats collected from contact chickens 
resulted in the formation of plaques, which were visualized by IFA (Fig. 29). 
Furthermore, buffy coat DNA from contact birds was analyzed for meq gene by PCR 
(data not shown). All five recombinant viruses were positive for Meq PCR. All the 
above results indicate that rMd5-Md5/CVI-Meq, and rMd5-CVI/Md5-Meq viruses can 
transmit horizontally among chickens. 
 
Fig. 29. Virus isolation in contact chickens. Lymphocytes were collected from contact 
chickens from each group and used to infect fresh DEF. Cells were stained 7 days post 
inoculation with H19 pp38 monoclonal antibody. 
 
 
3.4. Discussion 
MDV is regarded as one of the most potent oncogenic herpesviruses since it 
induces lethal T lymphomas in chickens as rapidly as 3 weeks, suggesting a direct role 
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for one or more viral proteins in the transformation process (Calnek, 2001). Search for 
such proteins has led to the discovery of Meq, a bZIP protein, which is highly expressed 
in both tumors and MDV-transformed cell lines (Jones et al., 1992). Based on in vitro 
transformation assays, it was suggested that Meq has the potential to function as an 
oncoprotein (Levy et al., 2005; Liu et al., 1999a; Liu et al., 1998; Qian et al., 1995). 
Subsequent experiments in chickens with a Meq knockout virus convincingly proved 
that Meq is the major oncogenic determinant of MDV (Brown et al., 2006; Lupiani et al., 
2004). Following these findings, three studies that focused on the mechanisms of Meq 
mediated transformation, critical for the design of new MDV vaccines, have been 
published. First, Meq has been suggested to transform via the v-Jun pathway since it 
activates genes such as JTAP-1, JAC, and HB-EGF (Levy et al., 2005). Second, like 
EBNA 3A and 3C of Epstein-Barr virus, Meq has also been shown to interact, through a 
motif located in its DNA binding domain, with C-terminal binding protein (CtBP) and 
this interaction has been demonstrated to be critical for transformation (Brown et al., 
2006). Finally, a recent work in our lab has indicated that homodimerization of Meq is 
insufficient for inducing tumors in chickens (Suchodolski et al., 2009).  
We have previously shown that while Md5-Meq and CVI-Meq proteins are able 
to equally transform rat and mouse embryonic fibroblasts, they differ in their 
transactivation activity on the meq promoter.  Interestingly, chimeric Meq proteins in 
which the DNA binding and transactivation domains had been swapped between Md5-
Meq and CVI-Meq showed intermediate transactivation activity on the meq promoter 
(Ajithdoss et al., 2009). While Md5 causes MD in 100% of infected chickens, a 
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recombinant Md5 virus expressing the Meq proteins from the attenuated vaccine strain 
CVI988 only caused MD in 6.6 % of inoculated chickens (Reddy and Lupiani, 
unpublished results). The main objective of this research was to identify the domains of 
the Meq protein of a very virulent strain, Md5, involved in transformation. To address 
this we constructed and studied the growth, transmission, and transformation properties 
of two chimeric Meq proteins, Md5/CVI-Meq and CVI/Md5-Meq, in the context of 
other Md5 genes. These chimeric proteins were constructed by swapping domains 
between Md5-Meq and CVI-Meq. It has been previously shown that the Meq is not 
essential for viral replication in cell culture (Lupiani et al., 2004). In agreement with this 
study, our results showed that the two chimeric Meq proteins did not alter the replication 
of the virus in vitro. In addition, analysis of early cytolytic replication of rMd5-
Md5/CVI-Meq and rMd5-CVI/Md5-Meq in lymphoid organs (spleen, bursa, and 
thymus) indicated that their replication was comparable to that of rMd5. Thus, chimeric 
Meq proteins do not affect in vivo replication of the virus.  
It is well known that MDV is a highly contagious virus since it rapidly spreads 
among susceptible chickens. Several MDV genes such as US2, UL13, gC, and LORF11 
affect the horizontal transmission of the virus (Jarosinski et al., 2007; Lee et al., 2007). 
However, thus far transmission has not been shown to be affected by Meq (Lupiani et 
al., 2004). In corroboration with this study, rMd5-Md5/CVI-Meq and rMd5-CVI/Md5-
Meq viruses were able to spread to other chickens as indicated by virus replication in 
both FFE and contact birds. Therefore, it is concluded that chimeric Meq proteins do not 
affect the transmission of virus. 
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The hallmark of MDV infection in chickens is the transformation of T 
lymphocytes. In this regard, both chimeric proteins induced lymphomas in chickens, but 
some differences were observed in the transformation phenotypes. First, Md5/CVI-Meq 
caused 100% mortality with mean death time of 33.3 days where as CVI/Md5-Meq on 
average caused 36 % mortality with mean death time of 42.3 days. Second, Md5/CVI-
Meq induced 100 % lesions in peripheral nerves and 53.3 % gross lesions in visceral 
organs whereas CVI/Md5-Meq induced tumor lesions primarily in the nerves (36 %) and 
rarely in visceral organs (7.5 %). rMd5 caused 100 % mortality with mean death time of 
37.1 days. Lesions were mainly in the nerves (100%) and were less frequently present in 
visceral organs (26%). Witter (1997) reported that high incidence of visceral lymphomas 
was associated with very virulent plus MDV strains (Witter, 1997), suggesting that the 
frequency of gross MD lesions in visceral organs is greatly influenced by the virulence 
of the virus. Our study showed that rMd5-Md5/CVI-Meq is more virulent than rMd5-
CVI/Md5-Meq and even rMd5 as the tumors were more aggresive. The data suggest that 
Meq is responsible for the difference in transformation phenotypes. 
In the present study, Md5-Meq, Md5/CVI-Meq and CVI/Md5-Meq, all in the 
context of Md5 genes, caused lesions in visceral organs, albeit at varying rates. Md5-
Meq caused tumors at low frequency in the heart and spleen whereas CVI/Md5-Meq 
rarely induced lesions in the heart and spleen. Quite strikingly, Md5/CVI-Meq induced 
lymphomas not only in the heart, and spleen, but also in the kidney, and gonads at a high 
rate and also caused lesions at lower levels in the intestines, pancreas, proventriculus, 
and liver. It is noteworthy that these tumors were generally bigger in size than those 
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induced by rMd5. Interestingly, the amino acid sequence of Md5/CVI-Meq, except at 
position 326 (T instead of I) in the transactivation domain, is similar to that of Meq of 
GA strain, which is known to cause only tumors in the liver, kidney, spleen, and gonads, 
but no nerve lesions in young chickens (Eidson and Schmittle, 1968). Like rMd5-
Md5/CVI-Meq, GA induces larger tumors. The DNA binding domain of Md5-Meq, 
Md5/CVI-Meq, and GA-Meq is identical whereas Md5/CVI-Meq, and GA-Meq have 
similar transactivation domain that is different from Md5-Meq. Since Md5/CVI-Meq, 
and GA-Meq, unlike Md5-Meq, cause tumors in the kidney and gonads at higher rate, 
this kind of tissue distribution could be attributed to their transactivation domain. 
However, it is important to note that the transactivation domain alone can not be 
responsible for this phenotype because CVI-Meq, which cause only nerve lesions in the 
background Md5 genes have same transactivation domain as Md5/CVI-Meq, and GA-
Meq but differ in their DNA binding domain. In other words, phenotypic changes 
observed with rMd5/CVI-Meq and rCVI/Md5-Meq could not be attributed to either 
DNA binding or transactivation domain alone. Based on these observations, we suggest 
that a combination of DNA binding domain and transactivation domain determines the 
incidence, nature and size of the tumors. It is important in the future to generate single 
amino acid mutant Meq viruses to understand the role of these six amino acids in the 
transformation process. 
The DNA binding domain of Meq is composed of two regions; (i) a basic amino 
acids rich region that binds DNA, and (ii) a leucine zipper motif, also known as 
dimerization domain, which facilitates dimerization. Meq through its basic region binds 
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specific sequences, known as MERE I, and MERE II, found in various promoters. Prior 
to binding to the DNA, it may dimerize with itself, forming homodimers or with various 
bZIP proteins, particularly c-Jun, forming heterodimers. Following binding to the DNA, 
the C-terminal domain of Meq can either activate or repress transcription depending 
upon the type of the promoter. These three regions of Meq, either alone or in cooperation 
could affect the development of tumors.  First, the basic region might influence where 
Meq binds, and in turn will regulate the genes that are critical for transformation. 
Because of difference in the basic regions, Md5/CVI-Meq and CVI/Md5-Meq might 
target different promoters. The knowledge about cellular promoters that are targeted by 
Meq is very limited. Importantly, there could be variation in their DNA binding 
affinities. Its DNA binding activity is affected by phosphorylation of serine at position 
42, which is present in both CVI/Md5-Meq and Md5/CVI-Meq. It is well established in 
case of Jun that phosphorylation reduces its DNA binding activity (Boyle et al., 1991, 
Oehler et al., 1993). Interestingly, CVI/Md5-Meq has a potential phosphorylation site at 
position 71. Whether these factors are responsible for the attenuated phenotype of 
CVI/Md5-Meq remains to be studied. Secondly, the homodimerization or 
heterodimerization of Meq or both might be crucial for transformation. The functions of 
bZIP proteins are largely affected by the interacting proteins. For example, Jun-Fos 
interaction confers anchorage independent growth while Jun-ATF2 interaction is 
responsible for serum independence (van Dam et al., 1998). Meq/Meq homodimers and 
Meq/Jun heterodimers have different functions. We have recently shown that Meq/Meq 
homodimers cannot cause tumors in chickens (Suchodolski et al., 2009). On the other 
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hand, heterodimerization of Meq can cause microscopic lesions in the nerves 
(Suchodolski et al.  manuscript under preparation). Because both Md5/CVI-Meq and 
CVI/Md5-Meq have identical leucine zipper region, it’s tempting to speculate that this 
region is less likely responsible for the transforming phenotype. It is important to note 
that there is serine at position 71 that can be phosphorylated in CVI/Md5-Meq whereas 
Md5/CVI-Meq has alanine at the same position. Interestingly, the DNA binding domains 
of Jun and of Meq are functionally exchangeable, which emphasizes the importance of 
phosphorylation. We have recently shown that Md5/CVI-Meq and CVI/Md5-Meq 
proteins, unlike CVI-Meq, transactivate the meq promoter, although at a lower level 
compared to Md5 Meq (Ajithdoss et al., 2009). Although Md5/CVI-Meq and CVI/Md5-
Meq proteins have comparable transactivation abilities in cell culture, it could not be 
correlated directly with their transformation properties. It is not surprising since such 
lack of direct correlation between transactivation activity and transformation has also 
been described for Jun (Havarstein et al., 1992). It is conceivable that the phenotypic 
differences between Md5-Meq and Md5/CVI-Meq are due to differences in the 
transactivation domain. In conclusion, it is clear that both DNA binding domain and 
transactivation domain of Meq contribute to the transformation phenotype. 
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4. SUMMARY 
Serotype 1 Marek’s disease virus (MDV-1) causes T cell lymphomas in 
chickens.  Attenuated and oncogenic MDV-1 strains code for an oncoprotein knows as 
Meq.  The overall objective of this study was to characterize the Meq proteins of the 
attenuated non-oncogenic MDV-1 vaccine strain CVI988/Rispens. Two forms of Meq 
proteins have been detected in CVI988/Rispens vaccinated chickens: CVI-Meq and 
CVI-L Meq. CVI-Meq and CVI-L Meq differ by six amino acids from Md5-Meq 
encoded by a very virulent MDV strain that causes lymphomas in chickens. In addition, 
CVI-LMeq contains a 59 amino acid insertion in its transactivation domain. It is 
noteworthy that Meq is essential for the development of lymphomas in chickens. We 
hypothesized that CVI-Meq and CVI-LMeq proteins lack transactivation and 
transformation activities due to these amino acid changes. 
In the current study, Md5-Meq protein bound and activated the meq promoter, in 
a dose-dependent fashion, in a luciferase reporter assay. In stark contrast, CVI-Meq and 
CVI-LMeq proteins failed to activate their own promoter even though they were able to 
bind. Interestingly, they activated the promoter in the presence of c-Jun overexpression. 
When co-transfected with Md5-Meq, CVI-Meq and CVI-LMeq proteins reduced the 
transactivation of the meq promoter in a dose-dependent manner. Thus, CVI-Meq and 
CVI-LMeq proteins could reduce the expression of Md5-Meq in case of Md5 super 
infection in CVI988/Rispens vaccinated chickens leading to no transformation possibly 
because of low levels of Md5-Meq. However, this hypothesis remains to be tested.  
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Unlike CVI-Meq proteins, chimeric Meq proteins CVI/Md5-Meq, Md5/CVI-
Meq, and Md5/CVI-LMeq, which were constructed by exchanging the DNA binding 
domain (DBD) and transactivation domain (TAD) among Md5- and CVI-Meq proteins, 
activated the the meq promoter, although to a significantly lower level than Md5-Meq 
protein. Thus, either the DNA binding domain or transactivation domain of Md5-Meq 
protein can confer transactivation function to CVI-Meq proteins. The above findings 
suggest: (1) the binding affinity of the DNA domain of CVI-Meq may not be as good as 
that of Md5-Meq (2) the transactivation ability of the transactivation domain of CVI-
Meq and CVI-LMeq is inferior to that of Md5-Meq, and (3) both domains are important 
for stronger transactivation activity by Md5-Meq. In the future, it is important to analyze 
the DNA binding affinities of parental and chimeric Meq proteins. 
Among the six amino acid residues in Md5-Meq that are different from CVI-
Meq, alanine at position 71, in the DNA binding domain, and threonine at position 320, 
in the transactivation domain, were important for transactivation. This further supports 
the importance of both domains in transactivation function. Interestingly, CVI-Meq 
proteins, have serine at position 71,which is a potential phosphorylation site. It will be 
interesting to study whether this serine is phosphorylated and if so, whether it modulates 
its DNA binding activity. Conversely, CVI-Meq proteins have an isoleucine at position 
320, resulting in a loss of phosphorylation residue when compared to Md5-Meq. 
Whether amino acid 320 is responsible for its lack of transactivation function in CVI-
Meq proteins could be studied by site-directed mutagenesis. Thus far, the 
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phosphorylation status of Meq is poorly understood. Our study suggests a potential role 
for phosphorylation in the biology of Meq that should be explored in the future. 
Md5-Meq, CVI-Meq and CVI-LMeq proteins suppressed transcription from the 
pp38/pp14 bidirectional early promoter as well as from the Meq binding sequence in the 
MDV Ori. These findings suggest that Meq may play a role in the maintenance of 
latency by suppressing the expression of early proteins pp38 and pp14. We showed, for 
the first time, that Meq can activate MDV gB, MMP-3, and Bcl-2 promoters. Although 
all three Meq proteins activated these promoters, activation by Md5-Meq was generally 
higher. 
CVI-Meq and CVI-LMeq proteins transformed NIH3T3 and Rat-2 fibroblast cell 
lines when overexpressed using a replication defective retrovirus system.  These 
transformed cells formed foci and colonies in soft agar very similar to Md5-Meq 
transformed cells. Therefore, the in vitro transformation ability of CVI-Meq and CVI-L 
Meq is not affected by the amino acid differences. Since MDV targets T cells for 
transformation, it is appropriate in the future to study the transformation properties of 
CVI-Meq and CVI-LMeq proteins using an in vitro chicken T cell system, which is 
lacking at present. 
To understand the role of Meq DNA binding and transactivation domains in the 
development of lymphomas, we constructed two recombinant rMd5 viruses: rMd5-
Md5/CVI-Meq (DNA binding domain of Md5-Meq and transactivation domain of CVI-
Meq) and rMd5-CVI/Md5-Meq (DNA binding domain of CVI-Meq and transactivation 
domain of Md5-Meq). rMd5, rMd5-CVI-Meq, rMd5-CVI-LMeq, rMd5-Md5/CVI-Meq 
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and rMd5-CVI/Md5-Meq viruses induced lymphomas in 100 %, 6%, 20%, 100% and 
36% of chickens, respectively. No disease was detected with CVI988/Rispens vaccine or 
control birds. All five recombinant viruses replicated well both in vitro and in vivo and 
all of them were capable causing infection in contact birds through horizontal 
transmission. 
Parental rMd5 caused 100% nerve lesions and 28% visceral lesions. rMd5-
Md5/CVI-Meq induced 100% lesions in nerves and 55% lesions in visceral organs 
whereas rMd5-CVI/Md5-Meq induced 36% lesions in nerves and 7% lesions in visceral 
organs. Type A nerve lesions, characterized by diffuse infiltration of lymphoid cells, 
were predominantly found in rMd5 and rMd5-Md5/CVI-Meq infected chickens. In 
contrast, rMd5-CVI/Md5-Meq induced commonly type C lesions, characterized by 
occasional lymphocyte infiltration in the nerves. rMd5 caused visceral lesions in the 
heart (15-33%) and the spleen (6-23%) and very rarely (6%) in the liver, gonads, and 
kidney. Interestingly, rMd5-Md5/CVI-Meq caused tumors in visceral organs at a 
significantly higher rate: heart (25-60%), spleen (20-50%), liver (0-26%), gonads (6-
25%) and kidney (35-60%). It is of interest that kidneys with tumors were at least 3 
times their normal size,.  On the other hand, rMd5-CVI/Md5-Meq induced very rarely 
lesions in the spleen (0-7%) and heart (0-8%) and no lesions in the kidney or gonads 
were observed.  
Our data collectively suggests that: (1) Md5/CVI-Meq is more oncogenic than 
CVI/Md5-Meq; (2) Md5/CVI-Meq is more or at least as oncogenic as Md5-Meq; (3) 
Md5/CVI-Meq retains the pathogenicity of Md5-Meq albeit containing the TAD of 
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CVI988/Rispens, thus indicating DBD plays an important role in transformation; (4) 
when compared to CVI-Meq, CVI/Md5-Meq, which contains the TAD of Md5, is more 
virulent, thus suggesting that the TAD also plays a role in transformation; (5) 
combination of DBD and TAD determines the transformation potential of Meq; and (6) 
Meq, is essential for transformation and plays a role in tumor dissemination.               
Based on the results presented here, future lines of research could include: (1) 
study whether the DNA binding domain or the transactivation domain of Meq alone can 
cause lymphomas in chickens; (2) study the role of individual amino acids, particularly 
residues at 71 and 320, in transformation by the generation of recombinant viruses; (3) to 
study the transformation properties of Md5-Meq in the context of CVI988 genes to 
better understand the role of other MDV genes in the transformation process; (4) to carry 
out microarray analysis in tumor cell lines derived from different recombinant viruses in 
order to identify genes that are regulated by Meq, especially those that play a role in 
tumor metastasis.  
In conclusion, CVI-Meq proteins transform fibroblasts and function as weak 
transcriptional factors in vitro. In addition, our studies proved that the DNA binding 
domain of CVI-Meq is not as efficient as that of Md5-Meq in inducing lymphomas and 
the transactivation domain of CVI-Meq may play a role in tumor dissemination. 
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